Navigating CAR-T Survivorship

11.28.23

Navigating CAR-T Survivorship

by ASTCT Talks

Hypomethylating agent maintenance after allo-HSCT for acute leukemia

11.23.23

Hypomethylating agent maintenance after allo-HSCT for acute leukemia

by ASTCT Science Highlights

CD19 CAR T-cell therapy and LTFU for relapsed/refractory CLL

11.21.23

CD19 CAR T-cell therapy and LTFU for relapsed/refractory CLL

by ASTCT Science Highlights

Giving Time, Making an Impact

11.21.23

Giving Time, Making an Impact

by Miguel Perales, MD

Beyond BCMA: Exploring Talquetamab in Myeloma Therapy

11.20.23

Beyond BCMA: Exploring Talquetamab in Myeloma Therapy

by ASTCT Talks

Announcing the Bone Marrow Transplant and Cellular Therapy Fellowship Database

11.17.23

Announcing the Bone Marrow Transplant and Cellular Therapy Fellowship Database

by Tristan Knight, MD FRCPC

Spatial transcriptomics biomarker for steroid-resistant aGVHD

11.16.23

Spatial transcriptomics biomarker for steroid-resistant aGVHD

by ASTCT Science Highlights

Allo-HCT outcomes for blastic plasmacytoid dendritic cell neoplasm

11.09.23

Allo-HCT outcomes for blastic plasmacytoid dendritic cell neoplasm

by ASTCT Science Highlights

TCRαß/CD19-cell depleted haploHSCT for children with acute leukemia

11.07.23

TCRαß/CD19-cell depleted haploHSCT for children with acute leukemia

by ASTCT Science Highlights

Behind the Scenes of CAR-T Therapy at University of California, Davis

11.01.23

Behind the Scenes of CAR-T Therapy at University of California, Davis

by ASTCT Talks

Fractionated Busulfan preparative regimen for alloHSCT

10.26.23

Fractionated Busulfan preparative regimen for alloHSCT

by ASTCT Science Highlights

Impact of GVHD Prophylaxis on CMV Reactivation and Disease After HLA-matched Peripheral Blood Stem Cell Transplantation

10.17.23

Impact of GVHD Prophylaxis on CMV Reactivation and Disease After HLA-matched Peripheral Blood Stem Cell Transplantation

by Alex Kadhim

Revitalize, Thrive, and Survive: The Power of Movement in Transplant Recovery

10.16.23

Revitalize, Thrive, and Survive: The Power of Movement in Transplant Recovery

by Miguel Perales, MD

Podcast Transcript for Revitalize, Thrive, and Survive: The Power of Movement in Transplant Recovery

10.16.23

Podcast Transcript for Revitalize, Thrive, and Survive: The Power of Movement in Transplant Recovery

by ASTCT Talks

Transcripción del Podcast de Revitalizar, Prosperar y Sobrevivir: El Poder del Movimiento en la Recuperación de los Trasplantes

10.16.23

Transcripción del Podcast de Revitalizar, Prosperar y Sobrevivir: El Poder del Movimiento en la Recuperación de los Trasplantes

by ASTCT Talks

Revitalizar, Prosperar y Sobrevivir: El Poder del Movimiento en la Recuperación de los Trasplantes

10.16.23

Revitalizar, Prosperar y Sobrevivir: El Poder del Movimiento en la Recuperación de los Trasplantes

by ASTCT Talks

Revitalize, Thrive, and Survive: The Power of Movement in Transplant Recovery

10.16.23

Revitalize, Thrive, and Survive: The Power of Movement in Transplant Recovery

by ASTCT Talks

A PTCy of Relief: GVHD Prophylaxis in Matched Unrelated Donors

10.12.23

A PTCy of Relief: GVHD Prophylaxis in Matched Unrelated Donors

by ASTCT Talks

CD24Fc for GVHD prevention in adults undergoing MUD HSCT

10.12.23

CD24Fc for GVHD prevention in adults undergoing MUD HSCT

by ASTCT Science Highlights

Notch Signaling Drives Intestinal Graft-versus-host Disease in Mice and Nonhuman Primates

10.11.23

Notch Signaling Drives Intestinal Graft-versus-host Disease in Mice and Nonhuman Primates

by Alex Kadhim

Pre-HCT gut microbiota diversity and outcomes in children

10.10.23

Pre-HCT gut microbiota diversity and outcomes in children

by ASTCT Science Highlights

Navigating Intersectionality in GVHD and Transplant Medicine

09.28.23

Navigating Intersectionality in GVHD and Transplant Medicine

by ASTCT Talks

Preclinical Characterization of ISB 1342, a CD38 × CD3 T-Cell Engager for Relapsed/Refractory Multiple Myeloma

09.28.23

Preclinical Characterization of ISB 1342, a CD38 × CD3 T-Cell Engager for Relapsed/Refractory Multiple Myeloma

by Alex Kadhim

Ultrasensitive chimerism after allo-HCT to augment MRD data

09.26.23

Ultrasensitive chimerism after allo-HCT to augment MRD data

by ASTCT Science Highlights

Advancing ALL Treatment and Insights on MRD Monitoring

09.18.23

Advancing ALL Treatment and Insights on MRD Monitoring

by ASTCT Talks

Embracing Autumn: A Season of Progress and Preparation

09.15.23

Embracing Autumn: A Season of Progress and Preparation

by Miguel Perales, MD

The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients

09.15.23

The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients

by Alex Kadhim

Measuring EASIX 1 year post-alloSCT to predict late NRM risk

09.14.23

Measuring EASIX 1 year post-alloSCT to predict late NRM risk

by ASTCT Science Highlights

Fludarabine AUC and outcomes following Axi-cel in aggressive B-NHL

09.12.23

Fludarabine AUC and outcomes following Axi-cel in aggressive B-NHL

by ASTCT Science Highlights

Ruxolitinib effect on aGVHD-related hematopoietic dysfunction

09.05.23

Ruxolitinib effect on aGVHD-related hematopoietic dysfunction

by ASTCT Science Highlights

MSC effect on thymic regulation to alleviate cGVHD

08.31.23

MSC effect on thymic regulation to alleviate cGVHD

by ASTCT Science Highlights

Newborn screening impact on survival after HCT for SCID

08.31.23

Newborn screening impact on survival after HCT for SCID

by ASTCT Science Highlights

Cyclophosphamide-tacrolimus-mycophenolate mofetil for post- HSCT GVHD prophylaxis

08.29.23

Cyclophosphamide-tacrolimus-mycophenolate mofetil for post- HSCT GVHD prophylaxis

by ASTCT Science Highlights

Children's Oncology Group AALL1331: Phase III Trial of Blinatumomab in Children, Adolescents, and Young Adults With Low-Risk B-Cell ALL in First Relapse

08.22.23

Children's Oncology Group AALL1331: Phase III Trial of Blinatumomab in Children, Adolescents, and Young Adults With Low-Risk B-Cell ALL in First Relapse

by Alex Kadhim

Monitoring After CAR-T Therapy for Multiple Myeloma: The APP Perspective

08.18.23

Monitoring After CAR-T Therapy for Multiple Myeloma: The APP Perspective

by ASTCT Talks

Exploring de novo late acute GVHD

08.17.23

Exploring de novo late acute GVHD

by ASTCT Science Highlights

Belumosudil Impacts Immunosuppression Pharmacokinetics in Patients with Chronic Graft-versus-Host Disease

08.10.23

Belumosudil Impacts Immunosuppression Pharmacokinetics in Patients with Chronic Graft-versus-Host Disease

by Alex Kadhim

A simplified function-first method for the discovery and optimization of bispecific immune engaging antibodies

08.08.23

A simplified function-first method for the discovery and optimization of bispecific immune engaging antibodies

by Alex Kadhim

Axi-cel outcome in treatment for R/R large B-cell lymphoma

08.01.23

Axi-cel outcome in treatment for R/R large B-cell lymphoma

by ASTCT Science Highlights

Pharmacy SIG Literature Update: A review of BMT CTN1703

07.28.23

Pharmacy SIG Literature Update: A review of BMT CTN1703

by ASTCT Pharmacy SIG Research Working Committee

Cyclosporine impact on tolerance induction after allo-HCT

07.27.23

Cyclosporine impact on tolerance induction after allo-HCT

by ASTCT Science Highlights

Dr. Eiko Hayase: Reflections On Winning the New Investigator Award Spotlight

07.25.23

Dr. Eiko Hayase: Reflections On Winning the New Investigator Award Spotlight

by Eiko Hayase, M.D., Ph.D

Dr. Stephen P. Persaud: Reflections On Winning the New Investigator Award Spotlight

07.24.23

Dr. Stephen P. Persaud: Reflections On Winning the New Investigator Award Spotlight

by Stephen P. Persaud, MD, PhD

Dr. Victor Tkachev: Reflections On Winning the New Investigator Award Spotlight

07.24.23

Dr. Victor Tkachev: Reflections On Winning the New Investigator Award Spotlight

by Victor Tkachev, Ph.D

Myeloablative haploBMT with PTCy for pediatric acute leukemias

07.24.23

Myeloablative haploBMT with PTCy for pediatric acute leukemias

by ASTCT Science Highlights

An off-the-shelf approach in identifying novel GVL mHAs

07.21.23

An off-the-shelf approach in identifying novel GVL mHAs

by Alex Kadhim

Titans of Transplant: Dr. Rick Jones

07.19.23

Titans of Transplant: Dr. Rick Jones

by ASTCT Talks

CMV reactivation and disease progression in response to different GVHD prophylaxis methods

07.18.23

CMV reactivation and disease progression in response to different GVHD prophylaxis methods

by Alex Kadhim

Abatacept GVHD prophylaxis in URD HCT for pediatric BM failure

07.18.23

Abatacept GVHD prophylaxis in URD HCT for pediatric BM failure

by ASTCT Science Highlights

A study of online patient resources for GVHD reveals information gaps

07.14.23

A study of online patient resources for GVHD reveals information gaps

by Alex Kadhim

A Melting Pot of Opportunity

07.12.23

A Melting Pot of Opportunity

by Miguel Perales, MD

Human DPTs directly involved in GVHD pathogenesis

07.06.23

Human DPTs directly involved in GVHD pathogenesis

by ASTCT Science Highlights

Motixafortide + G-CSF boosts CD34+ HSPCs in MM patients for ASCT

07.03.23

Motixafortide + G-CSF boosts CD34+ HSPCs in MM patients for ASCT

by ASTCT Science Highlights

Impact of cryopreserved grafts on transplant outcomes

06.30.23

Impact of cryopreserved grafts on transplant outcomes

by ASTCT Science Highlights

Teclistamab “Offers Substantial Clinical Benefit over Physician’s Choice of Therapy” in Triple-Class Exposed RRMM

06.26.23

Teclistamab “Offers Substantial Clinical Benefit over Physician’s Choice of Therapy” in Triple-Class Exposed RRMM

by Eleanor Mayfield, ELS

Podcast Transcript for Breaking Barriers and Dispelling Misconceptions in Transplantation

06.21.23

Podcast Transcript for Breaking Barriers and Dispelling Misconceptions in Transplantation

by Miguel Perales, MD

Breaking Barriers and Dispelling Misconceptions in Transplantation

06.20.23

Breaking Barriers and Dispelling Misconceptions in Transplantation

by Miguel Perales, MD

High Concordance Seen Between MRD Measurement by MFC and FGT in Infants with KMT2A-r ALL

06.19.23

High Concordance Seen Between MRD Measurement by MFC and FGT in Infants with KMT2A-r ALL

by Eleanor Mayfield, ELS

CAST regimen for acute GVHD prophylaxis after HSCT

06.13.23

CAST regimen for acute GVHD prophylaxis after HSCT

by ASTCT Science Highlights

NGS-MRD Panel Is “Highly Sensitive, Accurate” in AML

06.12.23

NGS-MRD Panel Is “Highly Sensitive, Accurate” in AML

by Eleanor Mayfield, ELS

Blinatumomab Added to Interfant-06 Chemotherapy “Safe and Efficacious” in Infants with Newly Diagnosed KMT2A-Rearranged ALL

06.09.23

Blinatumomab Added to Interfant-06 Chemotherapy “Safe and Efficacious” in Infants with Newly Diagnosed KMT2A-Rearranged ALL

by Eleanor Mayfield, ELS

Maintenance with ivosidenib post-HCT in IDH1-mutated AML

06.06.23

Maintenance with ivosidenib post-HCT in IDH1-mutated AML

by ASTCT Science Highlights

Pharmacy SIG Literature Update: Updated results from TRANSCEND with longer follow- up

06.02.23

Pharmacy SIG Literature Update: Updated results from TRANSCEND with longer follow- up

by ASTCT Pharmacy SIG Research Working Committee

Lenalidomide Maintenance and MRD 100 Days Post ASCT Predict PFS in Real-World Patient Cohort in Brazil

05.29.23

Lenalidomide Maintenance and MRD 100 Days Post ASCT Predict PFS in Real-World Patient Cohort in Brazil

by Eleanor Mayfield, ELS

Individualized Busulfan Dosing Improves Outcomes vs. Fixed Dosing in Pre-Transplant, MRD+, Intermediate-Risk AML Patients Receiving Allo-SCT

05.25.23

Individualized Busulfan Dosing Improves Outcomes vs. Fixed Dosing in Pre-Transplant, MRD+, Intermediate-Risk AML Patients Receiving Allo-SCT

by Eleanor Mayfield, ELS

You Can’t See the Forest for the Trees

05.22.23

You Can’t See the Forest for the Trees

by Miguel Perales, MD

How to Handle CAR-T Waitlists in Multiple Myeloma

05.18.23

How to Handle CAR-T Waitlists in Multiple Myeloma

by ASTCT Talks

Brentuximab vedotin consolidation post-ASCT in children with R/R HL

05.18.23

Brentuximab vedotin consolidation post-ASCT in children with R/R HL

by ASTCT Science Highlights

Multi-hit TP53MT impact on transplant outcome in myelofibrosis

05.16.23

Multi-hit TP53MT impact on transplant outcome in myelofibrosis

by ASTCT Science Highlights

Inflammatory CD4/CD8 double-positive human T cells arise from reactive CD8 T cells and are sufficient to mediate GVHD pathology

05.12.23

Inflammatory CD4/CD8 double-positive human T cells arise from reactive CD8 T cells and are sufficient to mediate GVHD pathology

by Alex Kadhim

Controlling ambient oxygen levels reduces severity of GI GVHD in murine models

05.11.23

Controlling ambient oxygen levels reduces severity of GI GVHD in murine models

by ASTCT Science Highlights

EAT It Up: In Preclinical Study, VEGF Blockade “Significantly Improves” Efficacy of Ex Vivo Armed T-Cells

05.11.23

EAT It Up: In Preclinical Study, VEGF Blockade “Significantly Improves” Efficacy of Ex Vivo Armed T-Cells

by Eleanor Mayfield, ELS

Ambient oxygen levels regulate intestinal dysbiosis and GVHD severity after allogeneic stem cell transplantation

05.10.23

Ambient oxygen levels regulate intestinal dysbiosis and GVHD severity after allogeneic stem cell transplantation

by Alex Kadhim

Value of DNA sequencing pre-HCT for AML patients

05.09.23

Value of DNA sequencing pre-HCT for AML patients

by ASTCT Science Highlights

In Multiple Myeloma, T-Cell Response to TCEs “Is Determined by Pre-Existing Cell State”

05.09.23

In Multiple Myeloma, T-Cell Response to TCEs “Is Determined by Pre-Existing Cell State”

by Eleanor Mayfield, ELS

Pre-Transplant DNA Sequencing Suggests Association Between Persistence of Most-Common AML Variants and Poorer Outcomes in Patients with AML

05.08.23

Pre-Transplant DNA Sequencing Suggests Association Between Persistence of Most-Common AML Variants and Poorer Outcomes in Patients with AML

by Eleanor Mayfield, ELS

Treating Cytopenias After CAR T-cell Therapy

05.08.23

Treating Cytopenias After CAR T-cell Therapy

by ASTCT Talks

A Pilot Trial of Patient-Reported Outcomes for Acute Graft-Versus-Host-Disease

05.04.23

A Pilot Trial of Patient-Reported Outcomes for Acute Graft-Versus-Host-Disease

by Alex Kadhim

In MajesTEC-1 Trial, Tocilizumab Reduced Recurrent CRS in Patients Treated with Teclistamab for RRMM

05.04.23

In MajesTEC-1 Trial, Tocilizumab Reduced Recurrent CRS in Patients Treated with Teclistamab for RRMM

by Eleanor Mayfield, ELS

Pharmacy SIG Literature Update: Haploidentical vs. MUD allogeneic transplants for lymphomas

05.03.23

Pharmacy SIG Literature Update: Haploidentical vs. MUD allogeneic transplants for lymphomas

by ASTCT Pharmacy SIG Research Working Committee

Sequence variation in NKG2D, MICA, and MICB affect risk of relapse post-HCT

04.25.23

Sequence variation in NKG2D, MICA, and MICB affect risk of relapse post-HCT

by ASTCT Science Highlights

Donor lymphocytes engineered with SA-FasL to avoid aGVHD

04.20.23

Donor lymphocytes engineered with SA-FasL to avoid aGVHD

by ASTCT Science Highlights

ddPCR, NGS “Are Promising Alternative Approaches to MRD Assessment in ALL”

04.19.23

ddPCR, NGS “Are Promising Alternative Approaches to MRD Assessment in ALL”

by Eleanor Mayfield, ELS

Bispecific Antibodies in Myeloma: The Who, What, When, and Where

04.18.23

Bispecific Antibodies in Myeloma: The Who, What, When, and Where

by ASTCT Talks

Abatacept for steroid-refractory cGVHD

04.18.23

Abatacept for steroid-refractory cGVHD

by ASTCT Science Highlights

Building a Brighter Future for HCT and CT

04.13.23

Building a Brighter Future for HCT and CT

by Miguel Perales, MD

Nanopore-Based Monitoring of Cell-Free DNA “Possible Biomarker in B-ALL”

04.11.23

Nanopore-Based Monitoring of Cell-Free DNA “Possible Biomarker in B-ALL”

by Eleanor Mayfield, ELS

Pharmacy SIG Literature Update: ATG in allogeneic HCT for AML

04.10.23

Pharmacy SIG Literature Update: ATG in allogeneic HCT for AML

by ASTCT Pharmacy SIG Research Working Committee

Virus-Specific T-Cells (VST): Where We Are and How We Got Here

04.06.23

Virus-Specific T-Cells (VST): Where We Are and How We Got Here

by ASTCT Talks

CD83 is a Promising GVHD Biomarker and Therapeutic Target

04.05.23

CD83 is a Promising GVHD Biomarker and Therapeutic Target

by Alex Kadhim

Study Finds Prognostic Impact of MRD Is Universal Across Treatment Regimens in Pediatric ALL, Regardless of When It Is Measured

04.03.23

Study Finds Prognostic Impact of MRD Is Universal Across Treatment Regimens in Pediatric ALL, Regardless of When It Is Measured

by Eleanor Mayfield, ELS

The Importance of Donor Age Over Donor Type

03.30.23

The Importance of Donor Age Over Donor Type

by Alex Kadhim

Women's History Month Spotlight: Nirali Shah, MD, MHSc

03.30.23

Women's History Month Spotlight: Nirali Shah, MD, MHSc

by Nirali Shah, MD, MHSc

Abatacept GVHD prophylaxis in URD HCT for pediatric BM failure

03.28.23

Abatacept GVHD prophylaxis in URD HCT for pediatric BM failure

by ASTCT Science Highlights

Women's History Month Spotlight: Betty Ky Hamilton, MD

03.28.23

Women's History Month Spotlight: Betty Ky Hamilton, MD

by Betty Ky Hamilton, MD

Women's History Month Spotlight: Nandita Khera, MD, MPH

03.24.23

Women's History Month Spotlight: Nandita Khera, MD, MPH

by Nandita Khera, MD, MPH

Women's History Month Spotlight: Kirsten Williams, MD

03.23.23

Women's History Month Spotlight: Kirsten Williams, MD

by Kirsten Williams, MD

Women's History Month Spotlight: Alison Gulbis, PharmD, BCOP

03.21.23

Women's History Month Spotlight: Alison Gulbis, PharmD, BCOP

by Alison Gulbis, PharmD, BCOP

Titans of Transplant: Dr. Micah Skeens

03.15.23

Titans of Transplant: Dr. Micah Skeens

by ASTCT Talks

Women's History Month Spotlight: Dianna Howard, MD

03.13.23

Women's History Month Spotlight: Dianna Howard, MD

by Dianna Howard, MD

Letermovir prophylaxis against CMV after HCT

03.13.23

Letermovir prophylaxis against CMV after HCT

by ASTCT Science Highlights

Combining TIGIT inhibition with immunomodulary drugs may prevent MM progression after SCT

03.09.23

Combining TIGIT inhibition with immunomodulary drugs may prevent MM progression after SCT

by ASTCT Science Highlights

GVHD is Maintained by Tissue-Resident TCF-1+ T Cells

03.09.23

GVHD is Maintained by Tissue-Resident TCF-1+ T Cells

by Alex Kadhim

Select in vivo expansion of oIL2Rß Tregs prevents acute GVHD in murine model

03.07.23

Select in vivo expansion of oIL2Rß Tregs prevents acute GVHD in murine model

by ASTCT Science Highlights

Study Provides First Preclinical Evidence of a Bispecific Trifunctional Antibody–Induced Anti-Tumor Vaccination Effect in Neuroblastoma

03.07.23

Study Provides First Preclinical Evidence of a Bispecific Trifunctional Antibody–Induced Anti-Tumor Vaccination Effect in Neuroblastoma

by Eleanor Mayfield, ELS

Women's History Month Spotlight: Lori Muffly, MD

03.06.23

Women's History Month Spotlight: Lori Muffly, MD

by Lori Muffly, MD

Oncolytic Adenovirus-Armed BiTEs “Could Overcome Limitations of BiTEs in Treatment of Solid Tumors”

03.03.23

Oncolytic Adenovirus-Armed BiTEs “Could Overcome Limitations of BiTEs in Treatment of Solid Tumors”

by Eleanor Mayfield, ELS

Viral-Specific T cell use in SCD patients post-HSCT

03.02.23

Viral-Specific T cell use in SCD patients post-HSCT

by ASTCT Science Highlights

CMV infection risk after PTCy in HLA-matched PBSC transplant

02.28.23

CMV infection risk after PTCy in HLA-matched PBSC transplant

by ASTCT Science Highlights

T-cell immunotherapies upregulate MHC-II surface expression on AML cells

02.21.23

T-cell immunotherapies upregulate MHC-II surface expression on AML cells

by ASTCT Science Highlights

Treg suppression mechanisms of acute GVHD

02.16.23

Treg suppression mechanisms of acute GVHD

by ASTCT Science Highlights

Cell Phones and Cell Therapies: Digital Health Innovations at #Tandem23

02.16.23

Cell Phones and Cell Therapies: Digital Health Innovations at #Tandem23

by Rahul Banerjee, MD, FACP

Ide-cel and kidney disease: the re(n)al-world experience with BCMA CAR-T

02.15.23

Ide-cel and kidney disease: the re(n)al-world experience with BCMA CAR-T

by Rahul Banerjee, MD, FACP

Liso-cel as second-line therapy for large B-cell lymphoma

02.14.23

Liso-cel as second-line therapy for large B-cell lymphoma

by ASTCT Science Highlights

MRD in ASC samples linked to high risk of relapse post-ASCT in R/R DLBCL

02.07.23

MRD in ASC samples linked to high risk of relapse post-ASCT in R/R DLBCL

by ASTCT Science Highlights

Pharmacy SIG Literature Update: PTCy pharmacokinetics and HaploHCT outcomes

02.07.23

Pharmacy SIG Literature Update: PTCy pharmacokinetics and HaploHCT outcomes

by ASTCT Pharmacy SIG Research Working Committee

ASTCT Talks: MRD in Relation to Transplantation and Cell Therapy

02.07.23

ASTCT Talks: MRD in Relation to Transplantation and Cell Therapy

by ASTCT Talks

Detectable MRD Associated with Increased Relapse Risk in AML Patients Treated With RIC, But Not MAC, Before Allo-HCT

02.02.23

Detectable MRD Associated with Increased Relapse Risk in AML Patients Treated With RIC, But Not MAC, Before Allo-HCT

by Eleanor Mayfield, ELS

Romiplostim impact post-auto HCT for multiple myeloma or lymphoma

02.02.23

Romiplostim impact post-auto HCT for multiple myeloma or lymphoma

by ASTCT Science Highlights

Every Step Taken: My Final ASTCT President’s Message

02.02.23

Every Step Taken: My Final ASTCT President’s Message

by Brenda M. Sandmaier, MD

Cross-Priming by CD40xTAA Bispecific Antibodies “Results in Superior Antitumor Response”

01.30.23

Cross-Priming by CD40xTAA Bispecific Antibodies “Results in Superior Antitumor Response”

by Eleanor Mayfield, ELS

Shared Minor Histocompatibility Antigens

01.26.23

Shared Minor Histocompatibility Antigens

by ASTCT Science Highlights

S100A9 separates GVHD from GVL

01.24.23

S100A9 separates GVHD from GVL

by ASTCT Science Highlights

The Winter 'Tridemic' in Cellular Therapy

01.24.23

The Winter 'Tridemic' in Cellular Therapy

by ASTCT Talks

Study Suggests Possible Therapeutic Role for Inhibition of B-Catenin and FOXO3 Expression

01.23.23

Study Suggests Possible Therapeutic Role for Inhibition of B-Catenin and FOXO3 Expression

by Eleanor Mayfield, ELS

Infusion of Memory T cells after haplo-HSCT

01.19.23

Infusion of Memory T cells after haplo-HSCT

by ASTCT Science Highlights

FLT3-ITD MRD “Is a Strong Independent Prognostic Factor for Relapse and Death” in AML

01.18.23

FLT3-ITD MRD “Is a Strong Independent Prognostic Factor for Relapse and Death” in AML

by Eleanor Mayfield, ELS

F-652 plus corticosteroids treatment for GI GVHD

01.17.23

F-652 plus corticosteroids treatment for GI GVHD

by ASTCT Science Highlights

Cross-Priming by CD40xTAA Bispecific Antibodies “Results in Superior Antitumor Response”

01.13.23

Cross-Priming by CD40xTAA Bispecific Antibodies “Results in Superior Antitumor Response”

by Eleanor Mayfield, ELS

Small Study Finds Blinatumomab/Dasatinib Combination “Safe and Feasible” in Patients Aged Over 65 with Ph+ ALL

01.10.23

Small Study Finds Blinatumomab/Dasatinib Combination “Safe and Feasible” in Patients Aged Over 65 with Ph+ ALL

by Eleanor Mayfield, ELS

Pharmacy SIG Literature Update: MMUD with PTCy based GVHD prophylaxis vs. HaploHCT in AM

01.04.23

Pharmacy SIG Literature Update: MMUD with PTCy based GVHD prophylaxis vs. HaploHCT in AM

by ASTCT Pharmacy SIG Research Working Committee

Update on GVHD Biomarkers

01.03.23

Update on GVHD Biomarkers

by Alex Kadhim

Update on Regulatory T Cells for HCT: Exploring Bone Marrow Tregs

12.28.22

Update on Regulatory T Cells for HCT: Exploring Bone Marrow Tregs

by Alex Kadhim

Microbiota injury related to Conditioning Regimens

12.22.22

Microbiota injury related to Conditioning Regimens

by ASTCT Science Highlights

Impact of pre-HCT therapy on outcome in patients with AML

12.20.22

Impact of pre-HCT therapy on outcome in patients with AML

by ASTCT Science Highlights

Outcomes of blood and marrow transplantation in children less than 2-years of age: 23 years of experience at a single center

12.15.22

Outcomes of blood and marrow transplantation in children less than 2-years of age: 23 years of experience at a single center

by Alex Kadhim

Impact of HSCT on VOEs requiring medical care SCD patients

12.15.22

Impact of HSCT on VOEs requiring medical care SCD patients

by ASTCT Science Highlights

Allo-HCT outcomes in older and medical infirm AML patients

12.13.22

Allo-HCT outcomes in older and medical infirm AML patients

by ASTCT Science Highlights

Year-end Evaluation: A “To Do” or an Opportunity?

12.12.22

Year-end Evaluation: A “To Do” or an Opportunity?

by Brenda M. Sandmaier, MD

Novel Therapeutic Strategies “Highlight Need to Understand Underlying Molecular Processes” in Hematologic Cancers

12.12.22

Novel Therapeutic Strategies “Highlight Need to Understand Underlying Molecular Processes” in Hematologic Cancers

by Eleanor Mayfield, ELS

Titans of Transplant: Susan Slater, MN, FNP-BC

12.07.22

Titans of Transplant: Susan Slater, MN, FNP-BC

by ASTCT Talks

Plant-Based Diet, Butyrate Production “Associated With Sustained MRD Negativity in Multiple Myeloma

12.06.22

Plant-Based Diet, Butyrate Production “Associated With Sustained MRD Negativity in Multiple Myeloma

by Eleanor Mayfield, ELS

Pharmacy SIG Literature Update: Impact of anti-T-lymphocyte globulin dosing on GVHD in MUD SC

12.06.22

Pharmacy SIG Literature Update: Impact of anti-T-lymphocyte globulin dosing on GVHD in MUD SC

by ASTCT Pharmacy SIG Research Working Committee

CAR-NK activity targets CLL-1 in AML

11.29.22

CAR-NK activity targets CLL-1 in AML

by ASTCT Science Highlights

UCART19 for adults with r/r B-ALL

11.24.22

UCART19 for adults with r/r B-ALL

by ASTCT Science Highlights

Risk of SMN in pediatric ALL patients after TBI conditioning

11.22.22

Risk of SMN in pediatric ALL patients after TBI conditioning

by ASTCT Science Highlights

Peripheral T helper cells in chronic GVHD

11.17.22

Peripheral T helper cells in chronic GVHD

by ASTCT Science Highlights

Safety of autologous freshly expanded mesenchymal stromal cells for the treatment of graft-versus-host disease

11.17.22

Safety of autologous freshly expanded mesenchymal stromal cells for the treatment of graft-versus-host disease

by Alex Kadhim

Giving Thanks and Giving Back

11.15.22

Giving Thanks and Giving Back

by Brenda M. Sandmaier, MD

Extracorporeal photopheresis versus standard treatment for acute graft-versus-host disease after haematopoietic stem cell transplantation in children and adolescents

11.14.22

Extracorporeal photopheresis versus standard treatment for acute graft-versus-host disease after haematopoietic stem cell transplantation in children and adolescents

by Alex Kadhim

Itacitinib treatment for LR GVHD

11.10.22

Itacitinib treatment for LR GVHD

by ASTCT Science Highlights

Pharmacy SIG Literature Update: BuCY versus CY/TBI for Standard Risk B-ALL in CR1 and More

11.09.22

Pharmacy SIG Literature Update: BuCY versus CY/TBI for Standard Risk B-ALL in CR1 and More

by ASTCT Pharmacy SIG Research Working Committee

HCT-CI score impact on NMA HSCT outcome for older AML patients

11.08.22

HCT-CI score impact on NMA HSCT outcome for older AML patients

by ASTCT Science Highlights

Insights on Emerging CAR T Therapies

11.01.22

Insights on Emerging CAR T Therapies

by

Fli-1 Regulates T Cell Immunity in GVHD

11.01.22

Fli-1 Regulates T Cell Immunity in GVHD

by ASTCT Science Highlights

TCRvß-CARTs Eliminates Malignant T-cell Clones

10.27.22

TCRvß-CARTs Eliminates Malignant T-cell Clones

by ASTCT Science Highlights

Monkeypox in HCT and CAR T

10.26.22

Monkeypox in HCT and CAR T

by ASTCT Talks

Late Effects in MCL Patients

10.25.22

Late Effects in MCL Patients

by ASTCT Science Highlights

Recent Multicenter Reviews Highlight the Need for aGVHD Treatment Options

10.21.22

Recent Multicenter Reviews Highlight the Need for aGVHD Treatment Options

by Alex Kadhim

Inhibition of TGF-ß1 signaling restores NK cell anti-leukemia responses

10.18.22

Inhibition of TGF-ß1 signaling restores NK cell anti-leukemia responses

by ASTCT Science Highlights

Normalization of Cerebral Hemodynamics Post-HSCT for SCD

10.13.22

Normalization of Cerebral Hemodynamics Post-HSCT for SCD

by ASTCT Science Highlights

Pharmacy SIG Literature Update: Pre-transplant Conditioning for AML/MDS with Fludarabine

10.11.22

Pharmacy SIG Literature Update: Pre-transplant Conditioning for AML/MDS with Fludarabine

by ASTCT Pharmacy SIG Research Working Committee

Immune Cell Profiling in Severe aGVHD

10.11.22

Immune Cell Profiling in Severe aGVHD

by ASTCT Science Highlights

Titans of Transplant: Dr. John F. DiPersio

10.10.22

Titans of Transplant: Dr. John F. DiPersio

by ASTCT Talks

Cooling Down or Heating Up

10.10.22

Cooling Down or Heating Up

by Brenda M. Sandmaier, MD

TCR Gene-modified Peripheral Blood T cells Against Metastatic Melanoma

10.06.22

TCR Gene-modified Peripheral Blood T cells Against Metastatic Melanoma

by ASTCT Science Highlights

Hispanic History Month Spotlight: Dr. Eneida R. Nemecek

10.04.22

Hispanic History Month Spotlight: Dr. Eneida R. Nemecek

by Dr. Eneida R. Nemecek

Biomarkers of Severe CRS and ICANS in B-ALL patients

10.04.22

Biomarkers of Severe CRS and ICANS in B-ALL patients

by ASTCT Science Highlights

Celebrating Advocacy Efforts, Overcoming Barriers and Addressing Inequity in Cellular Transplantation

09.28.22

Celebrating Advocacy Efforts, Overcoming Barriers and Addressing Inequity in Cellular Transplantation

by ASTCT Talks

Influence on CAR T-cell Outcomes of Race, Ethnicity, and BMI

09.26.22

Influence on CAR T-cell Outcomes of Race, Ethnicity, and BMI

by ASTCT Science Highlights

BiCisCAR Targeting Multiple TAAs Challenges Heterogeneous Expression in NB

09.22.22

BiCisCAR Targeting Multiple TAAs Challenges Heterogeneous Expression in NB

by ASTCT Science Highlights

Tandem 2022 Presentation: Haploidentical versus Matched Unrelated Donor Transplants for Lymphomas Using Post-transplant Cyclophosphamide

09.21.22

Tandem 2022 Presentation: Haploidentical versus Matched Unrelated Donor Transplants for Lymphomas Using Post-transplant Cyclophosphamide

by Andrés Gómez De León

Immunoregulatory Mechanisms Involving GvL Effect

09.19.22

Immunoregulatory Mechanisms Involving GvL Effect

by ASTCT Science Highlights

Allo-HCT for Ph+ ALL Patients in CR1 with CMR

09.15.22

Allo-HCT for Ph+ ALL Patients in CR1 with CMR

by ASTCT Science Highlights

TECing a Closer Look at Teclistamab with Dr. Saad Usmani

09.15.22

TECing a Closer Look at Teclistamab with Dr. Saad Usmani

by Rahul Banerjee, MD, FACP

Titans of Transplant: Dr. Rainer Storb

09.13.22

Titans of Transplant: Dr. Rainer Storb

by ASTCT Talks

Moonshot: Not Because It’s Easy

09.08.22

Moonshot: Not Because It’s Easy

by Brenda M. Sandmaier, MD

Pharmacy SIG Literature Update: Impact of Omitting Post-transplant mini-MTX Post alloHCT

09.06.22

Pharmacy SIG Literature Update: Impact of Omitting Post-transplant mini-MTX Post alloHCT

by ASTCT Pharmacy SIG Research Working Committee

The Interaction of HLA-C1/KIR2DL2/L3 Promoted KIR2DL2/L3 Single-Positive/NKG2C-Positive Natural Killer Cell Reconstitution, Raising the Incidence of aGVHD after Hematopoietic Stem Cell Transplantation

08.31.22

The Interaction of HLA-C1/KIR2DL2/L3 Promoted KIR2DL2/L3 Single-Positive/NKG2C-Positive Natural Killer Cell Reconstitution, Raising the Incidence of aGVHD after Hematopoietic Stem Cell Transplantation

by Alex Kadhim

BiTEs Complement CAR T Cell Use in Solid Tumors

08.30.22

BiTEs Complement CAR T Cell Use in Solid Tumors

by ASTCT Science Highlights

Serum Proteome Profiling of CRS and ICANS

08.30.22

Serum Proteome Profiling of CRS and ICANS

by ASTCT Science Highlights

ImmunoPET Allows Early Detection of Acute GI GVHD

08.23.22

ImmunoPET Allows Early Detection of Acute GI GVHD

by ASTCT Science Highlights

KIR-Favorable Haploidentical HCT in Children

08.18.22

KIR-Favorable Haploidentical HCT in Children

by ASTCT Science Highlights

Biomarkers Identify acute GVHD response to Itacitinib

08.16.22

Biomarkers Identify acute GVHD response to Itacitinib

by ASTCT Science Highlights

hUC-EVs-ATO Reduce the Severity of Acute GVHD by Resetting Inflammatory Macrophages Toward the M2 Phenotype

08.11.22

hUC-EVs-ATO Reduce the Severity of Acute GVHD by Resetting Inflammatory Macrophages Toward the M2 Phenotype

by Alex Kadhim

Impact of Anti-T-lymphocyte globulin dosing on GVHD and Immune reconstitution in matched unrelated myeloablative peripheral blood stem cell transplantation

08.11.22

Impact of Anti-T-lymphocyte globulin dosing on GVHD and Immune reconstitution in matched unrelated myeloablative peripheral blood stem cell transplantation

by Alex Kadhim

Enhanced AC133-Specific CAR T Cell Therapy Induces Durable Remissions in Mice with Metastatic Small Cell Lung Cancer

08.09.22

Enhanced AC133-Specific CAR T Cell Therapy Induces Durable Remissions in Mice with Metastatic Small Cell Lung Cancer

by ASTCT Science Highlights

394,044 Steps: Every Step Counts

08.09.22

394,044 Steps: Every Step Counts

by Brenda M. Sandmaier, MD

Chimeric Anti-GPC3 sFv-CD3ε Receptor-Modified T Cells with IL7 Co-Expression for the Treatment of Solid Tumors" Molecular Therapy — Oncolytics

08.04.22

Chimeric Anti-GPC3 sFv-CD3ε Receptor-Modified T Cells with IL7 Co-Expression for the Treatment of Solid Tumors" Molecular Therapy — Oncolytics

by ASTCT Science Highlights

Pharmacy SIG Literature Update: Post-transplant Cyclophosphamide for Prevention of Acute Graft versus Host Disease

08.03.22

Pharmacy SIG Literature Update: Post-transplant Cyclophosphamide for Prevention of Acute Graft versus Host Disease

by ASTCT Pharmacy SIG Research Working Committee

Long-Term Patient-Reported Neurocognitive Outcomes in Adult Survivors of Hematopoietic Cell Transplant

08.02.22

Long-Term Patient-Reported Neurocognitive Outcomes in Adult Survivors of Hematopoietic Cell Transplant

by ASTCT Science Highlights

Prospective External Validation of Biomarkers to Predict Acute Graft-Versus Host Disease Severity

07.21.22

Prospective External Validation of Biomarkers to Predict Acute Graft-Versus Host Disease Severity

by ASTCT Science Highlights

Comparative Effectiveness of ZUMA-5 (Axi-Cel) vs SCHOLAR-5 External Control in Relapsed/Refractory Follicular Lymphoma

07.19.22

Comparative Effectiveness of ZUMA-5 (Axi-Cel) vs SCHOLAR-5 External Control in Relapsed/Refractory Follicular Lymphoma

by ASTCT Science Highlights

The Times They Are A-Changin’

07.12.22

The Times They Are A-Changin’

by Brenda M. Sandmaier, MD

Titans of Transplant: Dr. Adriana Seber

07.11.22

Titans of Transplant: Dr. Adriana Seber

by ASTCT Talks

Dual-Specific CAR T Cell Expansion Improves Efficacy Against Solid Tumors in Mice

07.07.22

Dual-Specific CAR T Cell Expansion Improves Efficacy Against Solid Tumors in Mice

by ASTCT Science Highlights

Phenotypic Escape in CD19 -Directed Therapies

07.05.22

Phenotypic Escape in CD19 -Directed Therapies

by ASTCT Science Highlights

Transplant Outcomes in Adults with HLH

06.30.22

Transplant Outcomes in Adults with HLH

by ASTCT Science Highlights

Finding Affordable and Accessible Hematopoietic Cell Transplants

06.29.22

Finding Affordable and Accessible Hematopoietic Cell Transplants

by ASTCT Talks

Respiratory Viruses in Transplant Candidates

06.28.22

Respiratory Viruses in Transplant Candidates

by ASTCT Science Highlights

The 2022 ASTCT Tandem Meetings’ Spotlight Session on Delivering Culturally Sensitive Care: Conversations Between Patients and Their Providers

06.15.22

The 2022 ASTCT Tandem Meetings’ Spotlight Session on Delivering Culturally Sensitive Care: Conversations Between Patients and Their Providers

by Linda J. Burns, MD

Donor Plasmacytoid Dendritic Cells Limit GVHD

06.14.22

Donor Plasmacytoid Dendritic Cells Limit GVHD

by ASTCT Science Highlights

For Me: Spring has Sprung

06.14.22

For Me: Spring has Sprung

by Brenda M. Sandmaier, MD

Racial and Ethnic Diversity on Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Trials – We Can Do Better

06.13.22

Racial and Ethnic Diversity on Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Trials – We Can Do Better

by Linda J. Burns, MD

NOXA Role in CAR T-Cell Therapy for B-cell Malignancies

06.09.22

NOXA Role in CAR T-Cell Therapy for B-cell Malignancies

by ASTCT

Overcoming CAR-Mediated CD19 Downregulation

06.07.22

Overcoming CAR-Mediated CD19 Downregulation

by ASTCT

Pharmacy SIG Literature Update: PTCy in One-Antigen Mismatched URD HCT (1Ag-MMUD) Vs. HaploHCT in AML and More

06.03.22

Pharmacy SIG Literature Update: PTCy in One-Antigen Mismatched URD HCT (1Ag-MMUD) Vs. HaploHCT in AML and More

by ASTCT Pharmacy SIG Research Working Committee

Donor CIML NK Cells to Treat Post-HCT Relapse

06.02.22

Donor CIML NK Cells to Treat Post-HCT Relapse

by ASTCT

COVID-19 Vaccine Immune Response in Long-Term HSCT Survivors

05.31.22

COVID-19 Vaccine Immune Response in Long-Term HSCT Survivors

by ASTCT

CAR(NAP) T Cells Use in Murine Solid Tumors

05.26.22

CAR(NAP) T Cells Use in Murine Solid Tumors

by ASTCT Science Highlights

BiTE-Secreting T Cells “More Effective” At Eradicating Leukemia Than 2G CAR T CD19 Cells

05.25.22

BiTE-Secreting T Cells “More Effective” At Eradicating Leukemia Than 2G CAR T CD19 Cells

by ASTCT

MRD Positivity in Two IDH Variants Associated with Higher Post-HSCT Relapse Risk in Patients with AML

05.25.22

MRD Positivity in Two IDH Variants Associated with Higher Post-HSCT Relapse Risk in Patients with AML

by ASTCT

Zinc Promotes T Cell Reconstitution in Mouse Model of HSCT

05.24.22

Zinc Promotes T Cell Reconstitution in Mouse Model of HSCT

by ASTCT Science Highlights

Refined HLA-DPB1 Mismatch With Molecular Algorithms Predicts Outcomes in Hematopoietic Stem Cell Transplantation

05.20.22

Refined HLA-DPB1 Mismatch With Molecular Algorithms Predicts Outcomes in Hematopoietic Stem Cell Transplantation

by ASTCT

HuCART-19 Plus Ibrutinib Treatment in CLL

05.19.22

HuCART-19 Plus Ibrutinib Treatment in CLL

by ASTCT Science Highlights

Outcomes of Patients on Transplant Waiting Lists: Q&A with Dr. Giancarlo Fatobene

05.19.22

Outcomes of Patients on Transplant Waiting Lists: Q&A with Dr. Giancarlo Fatobene

by Andrés Gómez De León, MD

Impact of Genetic Factors at Diagnosis on HCT in Older AML Patients

05.17.22

Impact of Genetic Factors at Diagnosis on HCT in Older AML Patients

by ASTCT Science Highlights

Key differences in Immune Reconstitution Between ATLG and PTCy Treatments for Allogeneic Myeloablative Peripheral Blood Stem Cell Transplantation

05.16.22

Key differences in Immune Reconstitution Between ATLG and PTCy Treatments for Allogeneic Myeloablative Peripheral Blood Stem Cell Transplantation

by ASTCT

Use of PTCy in 1Ag-MMUD-HCT as a Valid Alternative to Haploidentical-HCT: A Study From the Acute Leukemia Working Party of the EBMT

05.11.22

Use of PTCy in 1Ag-MMUD-HCT as a Valid Alternative to Haploidentical-HCT: A Study From the Acute Leukemia Working Party of the EBMT

by ASTCT

CAR-NKT cells: More of a Goldilocks or a Kangaroo?

05.02.22

CAR-NKT cells: More of a Goldilocks or a Kangaroo?

by Rahul Banerjee, MD, FACP, and Jennifer Saultz, DO

Outcomes After Second-Line Treatment for Acute Graft-Versus-Host Disease

04.28.22

Outcomes After Second-Line Treatment for Acute Graft-Versus-Host Disease

by ASTCT Science Highlights

HLA-DQ Heterodimers in HCT

04.26.22

HLA-DQ Heterodimers in HCT

by ASTCT Science Highlights

Will CAR-T Therapy Replace Transplant in Myeloma and Lymphoma?

04.22.22

Will CAR-T Therapy Replace Transplant in Myeloma and Lymphoma?

by Rahul Banerjee, MD

Brain Microglia Senescence and Peripheral Macrophage Engraftment After HSCT

04.21.22

Brain Microglia Senescence and Peripheral Macrophage Engraftment After HSCT

by ASTCT Science Highlights

Vedolizumab in Highly Resistant Acute Gastrointestinal Graft-Versus-Host Disease After Allogeneic Stem Cell Transplantation: A Single-Center Pediatric Series

04.20.22

Vedolizumab in Highly Resistant Acute Gastrointestinal Graft-Versus-Host Disease After Allogeneic Stem Cell Transplantation: A Single-Center Pediatric Series

by ASTCT

BET-Bromodomain and EZH2 Inhibitor Treated Chronic GVHD Mice

04.19.22

BET-Bromodomain and EZH2 Inhibitor Treated Chronic GVHD Mice

by ASTCT Science Highlights

Safety and Efficacy of Tisagenlecleucel in Primary CNS Lymphoma

04.14.22

Safety and Efficacy of Tisagenlecleucel in Primary CNS Lymphoma

by ASTCT Science Highlights

Editorial: Naïve T-Cell Depletion to Prevent GVHD

04.13.22

Editorial: Naïve T-Cell Depletion to Prevent GVHD

by ASTCT

I Don’t Know Why We Say Goodbye…

04.12.22

I Don’t Know Why We Say Goodbye…

by ASTCT President Stella Davies

Factors Predicting Respiratory Viral Disease Progression in HCT Recipients

04.12.22

Factors Predicting Respiratory Viral Disease Progression in HCT Recipients

by ASTCT Science Highlights

A Risk Factor Analysis for GI/liver cGVHD

04.06.22

A Risk Factor Analysis for GI/liver cGVHD

by ASTCT

Titans of Transplant: Dr. Krishna Komanduri

04.04.22

Titans of Transplant: Dr. Krishna Komanduri

by ASTCT Talks

Anti-CAIX BBζ CAR4/8 T Cells Have Superior Efficacy in a ccRCC

03.31.22

Anti-CAIX BBζ CAR4/8 T Cells Have Superior Efficacy in a ccRCC

by ASTCT Science Highlights

Naive T-Cell Depletion to Prevent Chronic GVHD

03.29.22

Naive T-Cell Depletion to Prevent Chronic GVHD

by ASTCT Science Highlights

FACT Events at the 2022 Tandem Meetings in Salt Lake City

03.25.22

FACT Events at the 2022 Tandem Meetings in Salt Lake City

by Mikaela Vanmoorleghem

Naive T Cell Depletion Prevents Chronic Graft-Versus-Host Disease

03.25.22

Naive T Cell Depletion Prevents Chronic Graft-Versus-Host Disease

by ASTCT

Serum Neurofilaments Correlate With ICANS Severity

03.24.22

Serum Neurofilaments Correlate With ICANS Severity

by ASTCT Science Highlights

Letermovir Reduces Chronic GVHD Risk After Hematopoietic Cell Transplantation

03.23.22

Letermovir Reduces Chronic GVHD Risk After Hematopoietic Cell Transplantation

by ASTCT

Targeting Cancer-Associated Fibroblasts in Multiple Myeloma

03.22.22

Targeting Cancer-Associated Fibroblasts in Multiple Myeloma

by ASTCT Science Highlights

GVHD is Not Associated With Lower Relapse After HaploSCT With PTCy Treatment

03.18.22

GVHD is Not Associated With Lower Relapse After HaploSCT With PTCy Treatment

by ASTCT

PT-Cy For Prevention of Graft-Versus-Host Disease

03.17.22

PT-Cy For Prevention of Graft-Versus-Host Disease

by ASTCT Science Highlights

Managing COVID-19 in Transplant Patients

03.16.22

Managing COVID-19 in Transplant Patients

by ASTCT Talks

The Power of Recognition

03.16.22

The Power of Recognition

by Stella Davies, ASTCT President

Abatacept Treatment Can Reduce the Impact of Mismatching in Unrelated Donor Stem Cell Transplantation

03.16.22

Abatacept Treatment Can Reduce the Impact of Mismatching in Unrelated Donor Stem Cell Transplantation

by ASTCT

HCT for Wiskott-Aldrich Syndrome: An EBMT Inborn Errors Working Party Analysis

03.15.22

HCT for Wiskott-Aldrich Syndrome: An EBMT Inborn Errors Working Party Analysis

by ASTCT Science Highlights

BCMA/CD16a Tetravalent Antibody Shows “Modest Activity” Against RRMM in First-in-Humans Trial

03.10.22

BCMA/CD16a Tetravalent Antibody Shows “Modest Activity” Against RRMM in First-in-Humans Trial

by ASTCT

IFNg Not Necessary for CAR-T Efficacy in Hematologic Malignancies

03.10.22

IFNg Not Necessary for CAR-T Efficacy in Hematologic Malignancies

by ASTCT Science Highlights

Ex Vivo Study Identifies Determinants of Response to Bispecific Antibodies

03.08.22

Ex Vivo Study Identifies Determinants of Response to Bispecific Antibodies

by ASTCT

Manufacturing and Characterization of CMV-CD19 CAR T Cells

03.08.22

Manufacturing and Characterization of CMV-CD19 CAR T Cells

by ASTCT Science Highlights

Sickle Cell Disease: Dominique's story

03.07.22

Sickle Cell Disease: Dominique's story

by ASTCT

Durable MRD Negativity Associated with Improved PFS in Transplant-Ineligible NDMM

03.07.22

Durable MRD Negativity Associated with Improved PFS in Transplant-Ineligible NDMM

by ASTCT

Conversion to MRD Positivity “Conferred Inferior OS and PFS” in Multiple Myeloma

03.04.22

Conversion to MRD Positivity “Conferred Inferior OS and PFS” in Multiple Myeloma

by ASTCT

Women's History Month Spotlight: Amrita Krishnan, MD

03.03.22

Women's History Month Spotlight: Amrita Krishnan, MD

by Amrita Krishnan, MD

Cryopreserved Allogeneic Hematopoietic Grafts in the COVID-19 Pandemic

03.03.22

Cryopreserved Allogeneic Hematopoietic Grafts in the COVID-19 Pandemic

by ASTCT Science Highlights

Women's History Month Spotlight: Amanda Cashen, MD

03.02.22

Women's History Month Spotlight: Amanda Cashen, MD

by Amanda Cashen, MD

Neurocognitive and Movement Disorder After BCMA-Targeting CAR-T Cell Therapy

03.01.22

Neurocognitive and Movement Disorder After BCMA-Targeting CAR-T Cell Therapy

by ASTCT Science Highlights

Women's History Month Spotlight: Shernan Holtan, MD

03.01.22

Women's History Month Spotlight: Shernan Holtan, MD

by Shernan Holtan, MD

Pharmacy SIG Literature Update: Highlights of the 2021 American Society of Hematology Annual Meeting Updates

02.24.22

Pharmacy SIG Literature Update: Highlights of the 2021 American Society of Hematology Annual Meeting Updates

by ASTCT Pharmacy SIG Research Working Committee

Distinct CD4+ GM-CSF+ T Cell Lineage That Induces GI Tract GVHD

02.24.22

Distinct CD4+ GM-CSF+ T Cell Lineage That Induces GI Tract GVHD

by ASTCT Science Highlights

CD45-ADC Mediated Conditioning for Allogeneic HCT

02.22.22

CD45-ADC Mediated Conditioning for Allogeneic HCT

by ASTCT Science Highlights

Black History Month Spotlight: Melody Smith, MD, MS

02.21.22

Black History Month Spotlight: Melody Smith, MD, MS

by Melody Smith, MD, MS

Black History Month Spotlight: Brandon Blue, MD

02.18.22

Black History Month Spotlight: Brandon Blue, MD

by Brandon Blue, MD

Black History Month Spotlight: Allistair Abraham, MD

02.17.22

Black History Month Spotlight: Allistair Abraham, MD

by Allistair Abraham, MD

Day100 Score Predicts Moderate-Severe cGVHD, TRM, and Survival

02.17.22

Day100 Score Predicts Moderate-Severe cGVHD, TRM, and Survival

by ASTCT Science Highlights

Black History Month Spotlight: Rayne Rouce, MD

02.16.22

Black History Month Spotlight: Rayne Rouce, MD

by Rayne Rouce, MD

Titans of Transplant: Dr. Gregorio Jaimovich

02.15.22

Titans of Transplant: Dr. Gregorio Jaimovich

by ASTCT Talks

Black History Month Spotlight: Folashade Otegbeye, MBChB, MPH

02.15.22

Black History Month Spotlight: Folashade Otegbeye, MBChB, MPH

by Folashade Otegbeye, MBChB, MPH

Blinatumomab After Allo-HCT for B-lineage ALL

02.15.22

Blinatumomab After Allo-HCT for B-lineage ALL

by ASTCT Science Highlights

We Bend, Not Break

02.14.22

We Bend, Not Break

by ASTCT President, Stella Davies

Allogeneic HSC-Engineered iNKT Cells for Off-the-Shelf Cancer Immunotherapy

02.10.22

Allogeneic HSC-Engineered iNKT Cells for Off-the-Shelf Cancer Immunotherapy

by ASTCT Science Highlights

CAR-T Cell Quantification by cfDNA During Lymphoma Treatment

02.08.22

CAR-T Cell Quantification by cfDNA During Lymphoma Treatment

by ASTCT Science Highlights

Tisagenlecleucel Outcomes in R/R Extramedullary ALL

02.03.22

Tisagenlecleucel Outcomes in R/R Extramedullary ALL

by ASTCT Science Highlights

Cytogenetics Impact on CAR-T cell Therapy Outcomes

02.01.22

Cytogenetics Impact on CAR-T cell Therapy Outcomes

by ASTCT Science Highlights

AcCELLerate Forum: Final Session Recap

01.28.22

AcCELLerate Forum: Final Session Recap

by ASTCT

Analytical Approach For Identifying TAAs For CAR T Cell Therapy

01.27.22

Analytical Approach For Identifying TAAs For CAR T Cell Therapy

by ASTCT Science Highlights

Pharmacy SIG Literature Update: The Impact of GCSF With Thymoglobulin and More!

01.27.22

Pharmacy SIG Literature Update: The Impact of GCSF With Thymoglobulin and More!

by ASTCT Pharmacy SIG Research Working Committee

AcCELLerate Forum: Session 2 Recap

01.26.22

AcCELLerate Forum: Session 2 Recap

by ASTCT

Durable Antitumor Immunity With PRDM1 Knockout

01.25.22

Durable Antitumor Immunity With PRDM1 Knockout

by ASTCT Science Highlights

AcCELLerate Forum: Session 1 Recap

01.24.22

AcCELLerate Forum: Session 1 Recap

by ASTCT

Titans of Transplant: Dr. Mary Horowitz

01.24.22

Titans of Transplant: Dr. Mary Horowitz

by ASTCT Talks

The Impact of a Nursing Student

01.21.22

The Impact of a Nursing Student

by ASTCT

TAC Initial Steady State Level in PTCy GvHD Prophylaxis Regimen

01.20.22

TAC Initial Steady State Level in PTCy GvHD Prophylaxis Regimen

by ASTCT Science Highlights

Prefrontal Cortex Activity Correlates With Fatigue After HSCT

01.18.22

Prefrontal Cortex Activity Correlates With Fatigue After HSCT

by ASTCT Science Highlights

Update on GVHD Biomarkers

01.03.22

Update on GVHD Biomarkers

by Alex Kadhim

Anti-CD123 CAR T Cell Cytotoxicity Against AML

12.30.21

Anti-CD123 CAR T Cell Cytotoxicity Against AML

by ASTCT Abstracts

CAR T Cells Targeting TSHR Active Against Differentiated Thyroid Cancer

12.28.21

CAR T Cells Targeting TSHR Active Against Differentiated Thyroid Cancer

by ASTCT Abstracts

Peripheral Blood May Be “Adequate Alternative” to Bone Marrow for MRD Evaluation in Adults With ALL

12.24.21

Peripheral Blood May Be “Adequate Alternative” to Bone Marrow for MRD Evaluation in Adults With ALL

by ASTCT

PK-Guided Busulfan Conditioning Regimen for Allogeneic HCT

12.23.21

PK-Guided Busulfan Conditioning Regimen for Allogeneic HCT

by ASTCT Abstracts

Enhanced Reconstitution of γ δ T Cells Post-Transplant May Reduce Relapse Risk, Improve Survival in MRD+ AML

12.22.21

Enhanced Reconstitution of γ δ T Cells Post-Transplant May Reduce Relapse Risk, Improve Survival in MRD+ AML

by ASTCT

Ofatumumab and Prednisone for Chronic GVHD

12.21.21

Ofatumumab and Prednisone for Chronic GVHD

by ASTCT Abstracts

Nonrelapse Mortality Does Not Increase With Age in cGVHD

12.20.21

Nonrelapse Mortality Does Not Increase With Age in cGVHD

by ASTCT

Machine Learning Predicts GVHD and Post-Transplant Cyclophosphamide Signatures

12.17.21

Machine Learning Predicts GVHD and Post-Transplant Cyclophosphamide Signatures

by ASTCT

Cross-HLA Targeting of Intracellular Oncoproteins With Peptide-Centric CARs

12.16.21

Cross-HLA Targeting of Intracellular Oncoproteins With Peptide-Centric CARs

by ASTCT Abstracts

An Updated Analysis From The Chronic GVHD Consortium Finds Nonrelapse Mortality Increases Without Apparent Plateau in Patients With cGVHD

12.15.21

An Updated Analysis From The Chronic GVHD Consortium Finds Nonrelapse Mortality Increases Without Apparent Plateau in Patients With cGVHD

by ASTCT

Short-Chain Fatty Acid Receptor GPR109 Deficient T Cells Induce Less GVHD

12.14.21

Short-Chain Fatty Acid Receptor GPR109 Deficient T Cells Induce Less GVHD

by ASTCT Abstracts

Reasons to Believe

12.14.21

Reasons to Believe

by ASTCT President, Stella Davies

Severe CRS and Hematologic Toxicity After CAR T-Cell Therapy

12.09.21

Severe CRS and Hematologic Toxicity After CAR T-Cell Therapy

by ASTCT Abstracts

Your Guide to BMT & Cellular Therapy

12.08.21

Your Guide to BMT & Cellular Therapy

by ASTCT

Importance of HLA and Haploidentical Donor Selection

12.07.21

Importance of HLA and Haploidentical Donor Selection

by ASTCT Abstracts

What is BMT and Cellular Therapy?

12.07.21

What is BMT and Cellular Therapy?

by ASTCT

Allogeneic CAR iNKT Cells Induce Host CD8 T-Cell Antitumor Responses

12.02.21

Allogeneic CAR iNKT Cells Induce Host CD8 T-Cell Antitumor Responses

by ASTCT Abstracts

MSLN Directed CAR T-Cell Therapy in AML

11.30.21

MSLN Directed CAR T-Cell Therapy in AML

by ASTCT Abstracts

FACT Update

11.30.21

FACT Update

by Mikaela VanMoorleghem, FACT Education and Training Coordinator

Auto-HCT Outcome in Older CR1 AML Patients

11.25.21

Auto-HCT Outcome in Older CR1 AML Patients

by ASTCT Abstracts

Type 1 IFN Feasibility in Peri-HCT Period

11.23.21

Type 1 IFN Feasibility in Peri-HCT Period

by ASTCT Abstracts

CAR T Therapy, BiTES Key to “Spectacular” Progress Against R/R DLBCL

11.19.21

CAR T Therapy, BiTES Key to “Spectacular” Progress Against R/R DLBCL

by ASTCT

Rapamycin Pretreatment of EpCAM CAR-T Cells

11.18.21

Rapamycin Pretreatment of EpCAM CAR-T Cells

by ASTCT Abstracts

Donor Macrophage MHC II Role in CNS cGVHD

11.16.21

Donor Macrophage MHC II Role in CNS cGVHD

by ASTCT Abstracts

Review Authors Advocate Greater Use of Single-Arm Trials to Speed Development of Novel Treatment Modalities for Adult ALL

11.15.21

Review Authors Advocate Greater Use of Single-Arm Trials to Speed Development of Novel Treatment Modalities for Adult ALL

by ASTCT

MRD Predicts PFS, OS in Multiple Myeloma Following Stem Cell Transplant in Phase 3 Trial

11.12.21

MRD Predicts PFS, OS in Multiple Myeloma Following Stem Cell Transplant in Phase 3 Trial

by ASTCT

Auto-HCT or CAR T-Cell Therapy for DLBCL in PR

11.11.21

Auto-HCT or CAR T-Cell Therapy for DLBCL in PR

by ASTCT Abstracts

FT Regimen for Allo-HCT with MDS

11.09.21

FT Regimen for Allo-HCT with MDS

by ASTCT Abstracts

A Season of Gratitude and Thanks

11.09.21

A Season of Gratitude and Thanks

by Stella Davies, ASTCT President

IKZF1 Deletion Trumps MRD Status in Predicting Outcomes for Patients with ALL and Down Syndrome

11.08.21

IKZF1 Deletion Trumps MRD Status in Predicting Outcomes for Patients with ALL and Down Syndrome

by ASTCT

Pharmacy SIG Literature Update: A Focus CAR-T Therapies and Alternatives for Toxicity Management

10.29.21

Pharmacy SIG Literature Update: A Focus CAR-T Therapies and Alternatives for Toxicity Management

by ASTCT Pharmacy SIG Research Working Committee

Biomarker for BOS response after allo-HCT

10.28.21

Biomarker for BOS response after allo-HCT

by ASTCT Abstracts

CXCR4 and anti BCMA CAR on NK cells for MM therapy

10.26.21

CXCR4 and anti BCMA CAR on NK cells for MM therapy

by ASTCT Abstracts

Factors Affecting Tacrolimus Concentrations in Children with β-Thalassemia Major receiving HSCT

10.25.21

Factors Affecting Tacrolimus Concentrations in Children with β-Thalassemia Major receiving HSCT

by ASTCT

Interim Findings from the EQUATE Study Demonstrate Safety and Efficacy of Itolizumab

10.22.21

Interim Findings from the EQUATE Study Demonstrate Safety and Efficacy of Itolizumab

by ASTCT

SARS-CoV-2 Infection in HCT and CAR-T Recipients

10.21.21

SARS-CoV-2 Infection in HCT and CAR-T Recipients

by ASTCT Abstracts

COVID-19 Vaccine after Allo-HCT or CD19 CAR-T Therapy

10.19.21

COVID-19 Vaccine after Allo-HCT or CD19 CAR-T Therapy

by ASTCT Abstracts

KIR-ligand Mismatch in CBT Outcomes Differ Based on GVHD Prophylaxes

10.18.21

KIR-ligand Mismatch in CBT Outcomes Differ Based on GVHD Prophylaxes

by ASTCT

Reflectance Confocal Microscopy Shows Promise for GVHD Diagnosis

10.15.21

Reflectance Confocal Microscopy Shows Promise for GVHD Diagnosis

by ASTCT

Immunosuppressive Myeloid Cells for Tolerance in Solid Organ and HCT

10.14.21

Immunosuppressive Myeloid Cells for Tolerance in Solid Organ and HCT

by ASTCT Abstracts

Impact of TNF and IL-6R on GVHD

10.12.21

Impact of TNF and IL-6R on GVHD

by ASTCT Abstracts

Begin Again

10.12.21

Begin Again

by Stella Davies, ASTCT President

Meet ASTCT’s New Volunteer Editor

10.11.21

Meet ASTCT’s New Volunteer Editor

by ASTCT

The Impact of Graft CD3 Cell/Regulatory T Cell Ratio on Acute Graft-versus-Host Disease and Post-Transplantation Outcome: A Prospective Multicenter Study of Patients with Acute Leukemia

10.11.21

The Impact of Graft CD3 Cell/Regulatory T Cell Ratio on Acute Graft-versus-Host Disease and Post-Transplantation Outcome: A Prospective Multicenter Study of Patients with Acute Leukemia

by ASTCT

Post-transplant Multimorbidity Index and Quality of Life in Patients with Chronic Graft-Versus-Host Disease—Results From a Joint Evaluation of a Prospective German Multicenter Validation Trial

10.08.21

Post-transplant Multimorbidity Index and Quality of Life in Patients with Chronic Graft-Versus-Host Disease—Results From a Joint Evaluation of a Prospective German Multicenter Validation Trial

by ASTCT

HCT for DLBCL-Richter Transformation

10.07.21

HCT for DLBCL-Richter Transformation

by ASTCT Abstracts

Management of Allo-sensitized HCT Patients

10.05.21

Management of Allo-sensitized HCT Patients

by ASTCT Abstracts

Nonmyeloablative, HLA-Mismatched Unrelated Peripheral Blood Transplantation with High-Dose Post-Transplantation Cyclophosphamide

10.04.21

Nonmyeloablative, HLA-Mismatched Unrelated Peripheral Blood Transplantation with High-Dose Post-Transplantation Cyclophosphamide

by ASTCT

Extracorporeal Photopheresis in the Treatment of Acute Graft-Versus-Host Disease: A Multicenter Experience

10.01.21

Extracorporeal Photopheresis in the Treatment of Acute Graft-Versus-Host Disease: A Multicenter Experience

by ASTCT

Effects of off-the-shelf allogeneic CAR iNKT

09.30.21

Effects of off-the-shelf allogeneic CAR iNKT

by ASTCT Abstracts

German Analysis Finds MRD Testing by NGS Cost Effective for Multiple Myeloma

09.29.21

German Analysis Finds MRD Testing by NGS Cost Effective for Multiple Myeloma

by ASTCT

Impact of bNAb-derived CAR T cells in patients with HIV-1

09.28.21

Impact of bNAb-derived CAR T cells in patients with HIV-1

by ASTCT Abstracts

MRD Monitoring in Ph+ ALL: Digital Droplet PCR Outperforms Q-RT-PCR

09.27.21

MRD Monitoring in Ph+ ALL: Digital Droplet PCR Outperforms Q-RT-PCR

by ASTCT

Antigen loss a primary cause of CAR T cell resistance

09.23.21

Antigen loss a primary cause of CAR T cell resistance

by ASTCT Abstracts

Sequencing of Immunotherapeutic Agents for RR ALL in Adults – One Approach

09.22.21

Sequencing of Immunotherapeutic Agents for RR ALL in Adults – One Approach

by ASTCT

Pretransplant MRD impact for CBF-AML

09.21.21

Pretransplant MRD impact for CBF-AML

by ASTCT Abstracts

BiTEs and ADCs in RRMM: Long-Term Efficacy “Yet to Be Established”

09.20.21

BiTEs and ADCs in RRMM: Long-Term Efficacy “Yet to Be Established”

by ASTCT

Genetic variants associated with post-allo HCT CMV infection

09.16.21

Genetic variants associated with post-allo HCT CMV infection

by ASTCT Abstracts

Siglec-6-CAR T-cell therapy impact against AML in mice

09.14.21

Siglec-6-CAR T-cell therapy impact against AML in mice

by ASTCT Abstracts

CHIP impact on outcome of CAR T-cell therapy

09.09.21

CHIP impact on outcome of CAR T-cell therapy

by ASTCT Abstracts

Common Mission. Shared Purpose.

09.09.21

Common Mission. Shared Purpose.

by Stella Davies, ASTCT President

CMV GI disease viral load patterns after allo HCT

09.07.21

CMV GI disease viral load patterns after allo HCT

by ASTCT Abstracts

ADA Overexpression Boosts Anti-Tumor Effects of CAR T cells

09.02.21

ADA Overexpression Boosts Anti-Tumor Effects of CAR T cells

by ASTCT Abstracts

CAR T Therapies, BiTEs “Promising” in Follicular Lymphoma

09.01.21

CAR T Therapies, BiTEs “Promising” in Follicular Lymphoma

by ASTCT

Pharmacy SIG Literature Update: A Focus on Graft-Versus-Host Disease

08.31.21

Pharmacy SIG Literature Update: A Focus on Graft-Versus-Host Disease

by ASTCT Pharmacy SIG Research Working Committee

Thymus-Derived ILC2s From Id1tg/tg Mice Protect Against aGVHD

08.31.21

Thymus-Derived ILC2s From Id1tg/tg Mice Protect Against aGVHD

by ASTCT Abstracts

MAIA, ALCYONE Trials: Sustained MRD Negativity “Associated with Improved PFS” in Transplant-Ineligible NDMM

08.30.21

MAIA, ALCYONE Trials: Sustained MRD Negativity “Associated with Improved PFS” in Transplant-Ineligible NDMM

by ASTCT

D816V KIT Mutation, MRD Status “Significantly Associated” with Post-Transplant Relapse in AML with CBFB-MYH11 Mutation

08.27.21

D816V KIT Mutation, MRD Status “Significantly Associated” with Post-Transplant Relapse in AML with CBFB-MYH11 Mutation

by ASTCT

Ruxolitinib for Glucocorticoid-Refractory/-Dependent Chronic GVHD

08.26.21

Ruxolitinib for Glucocorticoid-Refractory/-Dependent Chronic GVHD

by ASTCT Abstracts

Anti-thymocyte globulin with CsA and MMF as GVHD prophylaxis in nonmyeloablative HLA-mismatched allogeneic HCT

08.25.21

Anti-thymocyte globulin with CsA and MMF as GVHD prophylaxis in nonmyeloablative HLA-mismatched allogeneic HCT

by ASTCT

Panobinostat Combination for Prevention of aGVHD

08.24.21

Panobinostat Combination for Prevention of aGVHD

by ASTCT Abstracts

Belumosudil for Chronic Graft-versus-Host Disease (cGVHD) After 2 or More Prior Lines of Therapy: The ROCKstar Study

08.23.21

Belumosudil for Chronic Graft-versus-Host Disease (cGVHD) After 2 or More Prior Lines of Therapy: The ROCKstar Study

by ASTCT

Itacitinib prevents xenogeneic GVHD in humanized mice

08.20.21

Itacitinib prevents xenogeneic GVHD in humanized mice

by ASTCT

A Transformative Career Development Workshop Through the ASTCT

08.19.21

A Transformative Career Development Workshop Through the ASTCT

by John Ligon

CAR.λ and CAR.κ-T cells potential alternatives to CAR.CD19-T cells in treating mature B-cell malignancies

08.19.21

CAR.λ and CAR.κ-T cells potential alternatives to CAR.CD19-T cells in treating mature B-cell malignancies

by ASTCT Abstracts

Rapamycin pretreatment strategy enhances the anti-AML efficacy of CAR T cells

08.17.21

Rapamycin pretreatment strategy enhances the anti-AML efficacy of CAR T cells

by ASTCT Abstracts

Posttransplant cyclophosphamide as GVHD prophylaxis for peripheral blood stem cell HLA-mismatched unrelated donor transplant

08.17.21

Posttransplant cyclophosphamide as GVHD prophylaxis for peripheral blood stem cell HLA-mismatched unrelated donor transplant

by ASTCT

Ruxolitinib for chronic steroid-refractory graft versus host disease: a single center experience

08.16.21

Ruxolitinib for chronic steroid-refractory graft versus host disease: a single center experience

by Alex Kadhim

CRP Ferritin and EASIX Score predict CAR-T–related toxicities

08.12.21

CRP Ferritin and EASIX Score predict CAR-T–related toxicities

by ASTCT Abstracts

Autoantibodies against the plakin family proteins as a novel marker for chronic graft-versus-host disease of the lung

08.11.21

Autoantibodies against the plakin family proteins as a novel marker for chronic graft-versus-host disease of the lung

by Alex Kadhim

Belumosudil for cGVHD

08.10.21

Belumosudil for cGVHD

by ASTCT Abstracts

Multiomics profiling shows heterogeneities in profiles of donor and patient CAR T cells

08.05.21

Multiomics profiling shows heterogeneities in profiles of donor and patient CAR T cells

by ASTCT Abstracts

MRD By MFC “A Strong Prognostic Factor” for Improved PFS and OS in Newly Diagnosed Multiple Myeloma

08.04.21

MRD By MFC “A Strong Prognostic Factor” for Improved PFS and OS in Newly Diagnosed Multiple Myeloma

by Eleanor Mayfield, ELS

When Awards Are More Than Just Awards

08.03.21

When Awards Are More Than Just Awards

by Stella Davies, ASTCT President

CD276-directed CAR T cells for treatment of ESCC

08.03.21

CD276-directed CAR T cells for treatment of ESCC

by ASTCT Abstracts

Pharmacy SIG Literature Update: Transplantation in Relapsed APL and More!

08.02.21

Pharmacy SIG Literature Update: Transplantation in Relapsed APL and More!

by ASTCT Pharmacy SIG Research Working Committee

A Deep Dive On Early Time-to-Toci

07.29.21

A Deep Dive On Early Time-to-Toci

by ASTCT Talks

Plasma MMP-9 in BOS after allo-HCT

07.29.21

Plasma MMP-9 in BOS after allo-HCT

by ASTCT Abstracts

Analysis of CASTOR and POLLUX Finds MRD Negativity Is Associated with Longer PFS

07.28.21

Analysis of CASTOR and POLLUX Finds MRD Negativity Is Associated with Longer PFS

by Eleanor Mayfield, ELS

FACT Update

07.27.21

FACT Update

by Mikaela VanMoorleghem

KTE-X19 in R/R B-cell ALL

07.27.21

KTE-X19 in R/R B-cell ALL

by ASTCT Abstracts

OV-BiTEs: A Promising Approach to Overcoming the Limitations of BiTEs?

07.26.21

OV-BiTEs: A Promising Approach to Overcoming the Limitations of BiTEs?

by Eleanor Mayfield, ELS

Building a Better BiTE: Strategies for Advancing the Therapeutic Potential of BiTEs

07.22.21

Building a Better BiTE: Strategies for Advancing the Therapeutic Potential of BiTEs

by Eleanor Mayfield, ELS

Functions of iNKT cell subsets

07.15.21

Functions of iNKT cell subsets

by ASTCT Abstracts

CMV seronegative recipients should receive CMV seronegative grafts

07.13.21

CMV seronegative recipients should receive CMV seronegative grafts

by ASTCT Abstracts

Outcome of COVID-19 in HCT patients

07.08.21

Outcome of COVID-19 in HCT patients

by ASTCT Abstracts

I’ve Got a Feeling…

07.06.21

I’ve Got a Feeling…

by Stella Davies, ASTCT President

PTCy associated with increased CMV infection

07.06.21

PTCy associated with increased CMV infection

by ASTCT Abstracts

Pharmacy SIG Literature Update: Tumor-Infiltrating Lymphocytes for Metastatic Melanoma and More

07.01.21

Pharmacy SIG Literature Update: Tumor-Infiltrating Lymphocytes for Metastatic Melanoma and More

by ASTCT Pharmacy SIG Research Working Committee

Clinical Value of MRD Testing Illustrated with Case Studies

06.22.21

Clinical Value of MRD Testing Illustrated with Case Studies

by Eleanor Mayfield, ELS

MRD “Has Prognostic Value” in Infant KMT2A-Rearranged ALL

06.18.21

MRD “Has Prognostic Value” in Infant KMT2A-Rearranged ALL

by Eleanor Mayfield, ELS

How We Coped and What We Learned During the COVID-19 Era: An ASTCT Review

06.18.21

How We Coped and What We Learned During the COVID-19 Era: An ASTCT Review

by The ASTCT Corporate Council

First BiTE at T-ALL? – A Potentially Promising New Approach to an Orphan Disease

06.16.21

First BiTE at T-ALL? – A Potentially Promising New Approach to an Orphan Disease

by Eleanor Mayfield, ELS

Early Signals of Safety and Efficacy for AMG 787 in Small-Cell Lung Cancer

06.14.21

Early Signals of Safety and Efficacy for AMG 787 in Small-Cell Lung Cancer

by Eleanor Mayfield, ELS

Advancements in Immunotherapies with Dr. DiPersio

06.10.21

Advancements in Immunotherapies with Dr. DiPersio

by ASTCT Talks

A SWOT Analysis of BiTEs

06.10.21

A SWOT Analysis of BiTEs

by Eleanor Mayfield, ELS

Signaling Through the Type 2 Cannabinoid Receptor Regulates the Severity of Acute and Chronic Graft-Versus-Host Disease

06.08.21

Signaling Through the Type 2 Cannabinoid Receptor Regulates the Severity of Acute and Chronic Graft-Versus-Host Disease

by Alex Kadhim

Severe Acute Graft-Versus-Host Disease Increases The Incidence of Blood Stream Infection and Mortality After Allogeneic Hematopoietic Cell Transplantation: Japanese Transplant Registry Study

06.04.21

Severe Acute Graft-Versus-Host Disease Increases The Incidence of Blood Stream Infection and Mortality After Allogeneic Hematopoietic Cell Transplantation: Japanese Transplant Registry Study

by Alex Kadhim

Dr. Hana Andrlova: Reflections On Winning the New Investigator Award

06.03.21

Dr. Hana Andrlova: Reflections On Winning the New Investigator Award

by ASTCT Headquarters

Predictors of Hematologic Malignancy Relapse in Patients with Advanced Chronic Graft-Versus-Host Disease

06.02.21

Predictors of Hematologic Malignancy Relapse in Patients with Advanced Chronic Graft-Versus-Host Disease

by Alex Kadhim

Here Comes the Sun (or Science)

06.01.21

Here Comes the Sun (or Science)

by Stella Davies, ASTCT President

In this Month’s Pharmacy SIG Literature Update: Single-Cord Blood Transplant vs. Haploidentical Stem Cell Transplantation

05.27.21

In this Month’s Pharmacy SIG Literature Update: Single-Cord Blood Transplant vs. Haploidentical Stem Cell Transplantation

by ASTCT Pharmacy SIG Research Working Committee

Outpatient Haploidentical Stem Cell Transplantation

05.25.21

Outpatient Haploidentical Stem Cell Transplantation

by ASTCT Talks

FACT Update

05.03.21

FACT Update

by Mikaela VanMoorleghem

In a Time of Change, We’re Driving Change

05.03.21

In a Time of Change, We’re Driving Change

by Stella Davies, ASTCT President

Use of Eltrombopag for the Treatment of Poor Graft Function after Hematopoietic Stem Cell Transplantation in Children

04.29.21

Use of Eltrombopag for the Treatment of Poor Graft Function after Hematopoietic Stem Cell Transplantation in Children

by Alex Kadhim

Reflections on Winning the New Investigator Award

04.27.21

Reflections on Winning the New Investigator Award

by ASTCT

Types, Clinical Features and Survival Outcomes of Patients with Acute Myeloid Leukemia in Thailand- A 3-year Prospective Multicenter Study from

04.27.21

Types, Clinical Features and Survival Outcomes of Patients with Acute Myeloid Leukemia in Thailand- A 3-year Prospective Multicenter Study from

by Alex Kadhim

Pharmacy SIG Literature Update: Chemotherapy vs. myeloablative alloHCT in AYA patients

04.26.21

Pharmacy SIG Literature Update: Chemotherapy vs. myeloablative alloHCT in AYA patients

by ASTCT Pharmacy SIG Research Working Committee

Progression of Self-Management Learning Experiences of Young Adults Following an Allogeneic Hematopoietic Stem Cell Transplantation_A Qualitative Study

04.23.21

Progression of Self-Management Learning Experiences of Young Adults Following an Allogeneic Hematopoietic Stem Cell Transplantation_A Qualitative Study

by Alex Kadhim

MRD Negativity “Associated with Improved Organ Response” in AL Amyloidosis

04.22.21

MRD Negativity “Associated with Improved Organ Response” in AL Amyloidosis

by Eleanor Mayfield, ELS

Nanoparticle-Based BiTEs “May Overcome Limitations” of Current Immunotherapies

04.19.21

Nanoparticle-Based BiTEs “May Overcome Limitations” of Current Immunotherapies

by Eleanor Mayfield, ELS

Passing of Dr. Francisco Marty

04.16.21

Passing of Dr. Francisco Marty

by Stella Davies, ASTCT President

Predictors of Outcomes of Therapy-Related Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation

04.16.21

Predictors of Outcomes of Therapy-Related Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation

by Alex Kadhim

MRD Positivity Associated with Worse Outcomes in Mantle Cell Lymphoma

04.15.21

MRD Positivity Associated with Worse Outcomes in Mantle Cell Lymphoma

by Eleanor Mayfield, ELS

Feasibility of an Intensified Myeloablative Conditioning Regimen Consisting of Busulfan, Fludarabine, Cytarabine, and Total Body Irradiation

04.14.21

Feasibility of an Intensified Myeloablative Conditioning Regimen Consisting of Busulfan, Fludarabine, Cytarabine, and Total Body Irradiation

by Alex Kadhim

Point–Counterpoint: BiTEs vs CAR T-cells

04.12.21

Point–Counterpoint: BiTEs vs CAR T-cells

by Eleanor Mayfield, ELS

Achieving More, Together

04.05.21

Achieving More, Together

by Stella Davies, ASTCT President

“Clear Benefit” Shown for Blinatumomab in High-Risk Relapsed Pediatric ALL

04.05.21

“Clear Benefit” Shown for Blinatumomab in High-Risk Relapsed Pediatric ALL

by Eleanor Mayfield, ELS

Pharmacy SIG Literature Update: TBI Myeloablative Conditioning in Haploidentical Transplants, Salvage Plerixafor for Poor Mobilizing Allogeneic Stem Cell Donors, and More

03.31.21

Pharmacy SIG Literature Update: TBI Myeloablative Conditioning in Haploidentical Transplants, Salvage Plerixafor for Poor Mobilizing Allogeneic Stem Cell Donors, and More

by Aaron Jennissen

Cardiovascular events associated with CAR-T cell therapy

03.31.21

Cardiovascular events associated with CAR-T cell therapy

by Abstracts Newsletter

Second HSCT “Crucial” to Relapse-Free Survival in Children with ALL Who Responded to Treatment with Blinatumomab

03.30.21

Second HSCT “Crucial” to Relapse-Free Survival in Children with ALL Who Responded to Treatment with Blinatumomab

by Eleanor Mayfield, ELS

Deletion of Cbl-b inhibits CAR T-cell exhaustion

03.30.21

Deletion of Cbl-b inhibits CAR T-cell exhaustion

by Abstracts Newsletter

Telomere length association with NRM in MDS post-SCT

03.30.21

Telomere length association with NRM in MDS post-SCT

by Abstracts Newsletter

Women's History Month Spotlight: Melody Smith, M.D.

03.29.21

Women's History Month Spotlight: Melody Smith, M.D.

by Melody Smith, M.D.

MRD Positivity Associated with Poorer PFS, OS, in Mantle Cell Lymphoma

03.29.21

MRD Positivity Associated with Poorer PFS, OS, in Mantle Cell Lymphoma

by Eleanor Mayfield, ELS

Targeting tissue-resident T cells a potential treatment pathway for cGVHD

03.29.21

Targeting tissue-resident T cells a potential treatment pathway for cGVHD

by Abstracts Newsletter

CAR T-cells targeting B-linage ALL irrespective of CD-19

03.26.21

CAR T-cells targeting B-linage ALL irrespective of CD-19

by Abstracts Newsletter

Treatment Options Expand for Relapsed or Refractory DLBCL

03.25.21

Treatment Options Expand for Relapsed or Refractory DLBCL

by Eleanor Mayfield, ELS

Stopping Treatment with MRD-Driven Three-Drug Regimen “Is Feasible” in Relapsed or Refractory Mantle Cell Lymphoma

03.24.21

Stopping Treatment with MRD-Driven Three-Drug Regimen “Is Feasible” in Relapsed or Refractory Mantle Cell Lymphoma

by Eleanor Mayfield, ELS

A Deep Dive on Chronic GVHD

03.24.21

A Deep Dive on Chronic GVHD

by ASTCT Talks

Women's History Month Spotlight: Laura Whited, PharmD, BCOP

03.23.21

Women's History Month Spotlight: Laura Whited, PharmD, BCOP

by Laura Whited, PharmD, BCOP

Sitagliptin prevention of aGVHD

03.23.21

Sitagliptin prevention of aGVHD

by Abstracts Newsletter

MRD Portends Poor Outcomes After ASCT for Patients with DLBCL

03.23.21

MRD Portends Poor Outcomes After ASCT for Patients with DLBCL

by Eleanor Mayfield, ELS

Local delivery of IL-12 boosts CAR-T cell therapy for GBM

03.23.21

Local delivery of IL-12 boosts CAR-T cell therapy for GBM

by Abstracts Newsletter

Evaluating risk factors for acute graft versus host disease in pediatric hematopoietic stem cell transplant patients receiving tacrolimus

03.19.21

Evaluating risk factors for acute graft versus host disease in pediatric hematopoietic stem cell transplant patients receiving tacrolimus

by Alex Kadhim

Women's History Month Spotlight: Stefanie Sarantopoulos, M.D., Ph.D.

03.19.21

Women's History Month Spotlight: Stefanie Sarantopoulos, M.D., Ph.D.

by Stefanie Sarantopoulos, M.D., Ph.D.

Women's History Month Spotlight: Linda J. Burns, M.D.

03.19.21

Women's History Month Spotlight: Linda J. Burns, M.D.

by Linda J. Burns, M.D.

Auto vs. Allo HCT for poor-risk peripheral T-NHL

03.19.21

Auto vs. Allo HCT for poor-risk peripheral T-NHL

by Abstracts Newsletter

Women's History Month Spotlight: Dianna Sue Howard, M.D.

03.18.21

Women's History Month Spotlight: Dianna Sue Howard, M.D.

by Dianna Sue Howard, M.D.

Women's History Month Spotlight: Tania Jain, M.B.B.S.

03.18.21

Women's History Month Spotlight: Tania Jain, M.B.B.S.

by Tania Jain, M.B.B.S.

Graft Versus Host Disease Associated with Immune Checkpoint Inhibitors

03.17.21

Graft Versus Host Disease Associated with Immune Checkpoint Inhibitors

by Alex Kadhim

Association of Graft-Versus-Host-Disease with Neurologic Complications- Clinical Paradigm and Future Directions

03.15.21

Association of Graft-Versus-Host-Disease with Neurologic Complications- Clinical Paradigm and Future Directions

by Alex Kadhim

Spatiotemporal single-cell profiling reveals that invasive and tissue-resident memory donor CD8+ T cells drive gastrointestinal acute graft-versus

03.12.21

Spatiotemporal single-cell profiling reveals that invasive and tissue-resident memory donor CD8+ T cells drive gastrointestinal acute graft-versus

by Alex Kadhim

Reflections On a New (Leadership) Year

03.02.21

Reflections On a New (Leadership) Year

by Stella Davies, MBBS, PhD

Pharmacy SIG Literature Update: Results of the BMT CTN 1101 Trial and More

03.01.21

Pharmacy SIG Literature Update: Results of the BMT CTN 1101 Trial and More

by Katie Gatwood

Inaugural Letter from FACT’s New President: Catherine M. Bollard, MBChB, MD, FRACP, FRCPA

03.01.21

Inaugural Letter from FACT’s New President: Catherine M. Bollard, MBChB, MD, FRACP, FRCPA

by Mikaela VanMoorleghem

BCMA-Targeted Therapies “Promising” in Multiple Myeloma

02.24.21

BCMA-Targeted Therapies “Promising” in Multiple Myeloma

by Eleanor Mayfield, ELS

MRD Negativity “Achievable” Even in High-Risk Refractory Multiple Myeloma

02.18.21

MRD Negativity “Achievable” Even in High-Risk Refractory Multiple Myeloma

by Eleanor Mayfield, ELS

Exact Sciences Acquires Rights to TARDIS Liquid Biopsy Technology

02.16.21

Exact Sciences Acquires Rights to TARDIS Liquid Biopsy Technology

by Eleanor Mayfield, ELS

American Society for Transplantation and Cellular Therapy Awards Dr. Anthony Fauci with 2021 Public Service Award

02.12.21

American Society for Transplantation and Cellular Therapy Awards Dr. Anthony Fauci with 2021 Public Service Award

by ASTCT

MRD “Key Component” in Treatment Selection for Transplant-Eligible Multiple Myeloma Patients

02.10.21

MRD “Key Component” in Treatment Selection for Transplant-Eligible Multiple Myeloma Patients

by Eleanor Mayfield, ELS

Pharmacy SIG Literature Update: Autologous Transplantation for Multiple Myeloma and More

02.03.21

Pharmacy SIG Literature Update: Autologous Transplantation for Multiple Myeloma and More

by Katie Gatwood

What a Difference a Year Makes

02.03.21

What a Difference a Year Makes

by Dr. Pavan Reddy, ASTCT President

FACT Update: New Editions of FACT-JACIE Hematopoietic Cell Therapy and FACT Immune Effector Cell Standards to be Published in May

01.14.21

FACT Update: New Editions of FACT-JACIE Hematopoietic Cell Therapy and FACT Immune Effector Cell Standards to be Published in May

by Mikaela VanMoorleghem, FACT Education and Training Coordinator

#TCTM21: A Virtual Meeting with Real-Life Tweeting

01.14.21

#TCTM21: A Virtual Meeting with Real-Life Tweeting

by Amar H. Kelkar, MD and Rahul Banerjee, MD

Join Us at the TCT Meetings of ASTCT and CIBMTR This Year

01.11.21

Join Us at the TCT Meetings of ASTCT and CIBMTR This Year

by Dr. Pavan Reddy, ASTCT President

The National Marrow Donor Program® (NMDP)/Be The Match’s HLA Today Program Offers Critical Information Early in a Patient’s Disease Course

01.06.21

The National Marrow Donor Program® (NMDP)/Be The Match’s HLA Today Program Offers Critical Information Early in a Patient’s Disease Course

by HLA Today

Pharmacy SIG Literature Update: A Novel Risk Assessment Tool for alloHCT in the Elderly and More

01.04.21

Pharmacy SIG Literature Update: A Novel Risk Assessment Tool for alloHCT in the Elderly and More

by Katie Gatwood

TCT Travel Grant Brings People Together—and Moves People Forward

12.11.20

TCT Travel Grant Brings People Together—and Moves People Forward

by Kate Jacobson

As BBMT Becomes TCT, A Look Back At the Beginning of Our Journal

12.08.20

As BBMT Becomes TCT, A Look Back At the Beginning of Our Journal

by Kate Jacobson

In a Year Fraught with Challenges, Remember Our Strengths

12.08.20

In a Year Fraught with Challenges, Remember Our Strengths

by Dr. Pavan Reddy, ASTCT President

Pharmacy SIG Literature Update: Haploidentical Transplantation in Aplastic Anemia and More

12.04.20

Pharmacy SIG Literature Update: Haploidentical Transplantation in Aplastic Anemia and More

by Katie Gatwood

MRD Negativity and Lenalidomide Maintenance Therapy: The Possible Next Chapter in Multiple Myeloma Care

12.02.20

MRD Negativity and Lenalidomide Maintenance Therapy: The Possible Next Chapter in Multiple Myeloma Care

by ASTCT Talks

Blocking a Fatty-Acid Metabolism Pathways Improves GVHD

12.01.20

Blocking a Fatty-Acid Metabolism Pathways Improves GVHD

by Alex Kadhim

ASTCT Leadership Course Shapes the Next Generation of Change Makers

11.20.20

ASTCT Leadership Course Shapes the Next Generation of Change Makers

by Kate Jacobson

Dr. Lia Gore Discusses Bispecific T-Cell Engagers in Pediatric ALL Research

11.12.20

Dr. Lia Gore Discusses Bispecific T-Cell Engagers in Pediatric ALL Research

by ASTCT Talks

Pharmacy Literature Update: Use of Post-Transplant Cyclophosphamide in Haploidentical HCT and More

11.02.20

Pharmacy Literature Update: Use of Post-Transplant Cyclophosphamide in Haploidentical HCT and More

by Katie Gatewood

Looking for a Way to Give Back this Holiday Season? Consider ASTCT

11.02.20

Looking for a Way to Give Back this Holiday Season? Consider ASTCT

by Dr. Pavan Reddy, ASTCT President

FACT Update: FACT Virtual Inspections in Response to COVID

10.30.20

FACT Update: FACT Virtual Inspections in Response to COVID

by Mikaela VanMoorleghem

MRD in Multiple Myeloma: “The Utility Is Undeniable,” Although Use in Clinical Decision Making is Premature

10.26.20

MRD in Multiple Myeloma: “The Utility Is Undeniable,” Although Use in Clinical Decision Making is Premature

by Eleanor Mayfield, ELS

New Investigator Using ASTCT Grant To Begin Next Step in His Career

10.21.20

New Investigator Using ASTCT Grant To Begin Next Step in His Career

by Kate Jacobson

Wherever We Meet, We Will Learn Together

10.14.20

Wherever We Meet, We Will Learn Together

by Pavan Reddy, MD

Pharmacy SIG Literature Update: Sorafenib Maintenance After Allogeneic Transplantation and More

10.12.20

Pharmacy SIG Literature Update: Sorafenib Maintenance After Allogeneic Transplantation and More

by Katie Gatwood

Survey: Clinicians Are Assessing MRD in Multiple Myeloma, but Demur at Using It to Make Treatment Decisions

09.30.20

Survey: Clinicians Are Assessing MRD in Multiple Myeloma, but Demur at Using It to Make Treatment Decisions

by Eleanor Mayfield, ELS

New Investigator Award Winner Says Research Wouldn’t Be Possible Without Organizations like ASTCT

09.18.20

New Investigator Award Winner Says Research Wouldn’t Be Possible Without Organizations like ASTCT

by Kate Jacobson

“Impressive” Results for Investigational BiTEs Seen in Phase 1 Myeloma Studies

09.18.20

“Impressive” Results for Investigational BiTEs Seen in Phase 1 Myeloma Studies

by Eleanor Mayfield, ELS

Incyte Announces Recipient of Incyte Ingenuity Award

09.18.20

Incyte Announces Recipient of Incyte Ingenuity Award

by Kate Jacobson

Policy Perspectives: FY 2021 IPPS Final Rule

09.11.20

Policy Perspectives: FY 2021 IPPS Final Rule

by Alycia Maloney

Never Too Old to Learn

09.11.20

Never Too Old to Learn

by Dr. Pavan Reddy, ASTCT President

STING Protein Pathway Can Protect Certain Patients from GVHD, Study Finds

09.10.20

STING Protein Pathway Can Protect Certain Patients from GVHD, Study Finds

by Kate Jacobson

FACT Update: Registration is Open for the FACT Inspection & Accreditation Virtual Workshop

09.10.20

FACT Update: Registration is Open for the FACT Inspection & Accreditation Virtual Workshop

by Mikaela VanMoorleghem

Pharmacy SIG Literature Update: Major Guideline Updates, Use of Reduced Intensity Conditioning Regimens and More

09.03.20

Pharmacy SIG Literature Update: Major Guideline Updates, Use of Reduced Intensity Conditioning Regimens and More

by Katie Gatwood

New Study Finds T-Cells Play Unappreciated Role in Acute GVHD

08.30.20

New Study Finds T-Cells Play Unappreciated Role in Acute GVHD

by Kate Jacobson

Best Practices in MRD Quantification: The Importance of the First Bone Marrow Pull

08.28.20

Best Practices in MRD Quantification: The Importance of the First Bone Marrow Pull

by Eleanor Mayfield, ELS

Emergence of Non-Steroid Treatments is One of Most “Exciting Developments” in GVHD, Doctor Says

08.21.20

Emergence of Non-Steroid Treatments is One of Most “Exciting Developments” in GVHD, Doctor Says

by Kate Jacobson

ASTCT Social Work SIG Hopes to Bring Important Resources to Hem/Onc Social Workers around the Country

08.21.20

ASTCT Social Work SIG Hopes to Bring Important Resources to Hem/Onc Social Workers around the Country

by Kate Jacobson

Leadership Means Being Part of the Solution

08.06.20

Leadership Means Being Part of the Solution

by Dr. Pavan Reddy, ASTCT President

FACT Update: Save the Date for Virtual Inspection and Accreditation Workshop

08.05.20

FACT Update: Save the Date for Virtual Inspection and Accreditation Workshop

by Mikaela VanMoorleghem

“Acceptable” Results in AMG 330 Phase I Dose-Escalation Study

08.03.20

“Acceptable” Results in AMG 330 Phase I Dose-Escalation Study

by Eleanor Mayfield, ELS

Pharmacy SIG Literature Update: GVHD Prophylaxis, Risk Assessment for SOS and TMA and More

07.31.20

Pharmacy SIG Literature Update: GVHD Prophylaxis, Risk Assessment for SOS and TMA and More

by Katie Gatwood

Defining the Role of Blinatumomab in Pediatric ALL

07.28.20

Defining the Role of Blinatumomab in Pediatric ALL

by Eleanor Mayfield, ELS

Dr. Roger Herzig, Dedicated BMT Physician, Dies at 74

07.27.20

Dr. Roger Herzig, Dedicated BMT Physician, Dies at 74

by Kate Jacobson

MRD Assessment in Early-Stage NSCLC “Would Be Practice Changing”

07.22.20

MRD Assessment in Early-Stage NSCLC “Would Be Practice Changing”

by Eleanor Mayfield, ELS

MRD Monitoring “Essential” in CML

07.20.20

MRD Monitoring “Essential” in CML

by Eleanor Mayfield, ELS

Transfusion Updates for the Pandemic Era

07.17.20

Transfusion Updates for the Pandemic Era

by Drs Garrett S. Booth and Bipin N. Savani

MRD “Meets Criteria for Broad Clinical Use”

07.13.20

MRD “Meets Criteria for Broad Clinical Use”

by Eleanor Mayfield, ELS

This Summer, Consider Giving to ASTCT to Support the Next Generation of Science

07.07.20

This Summer, Consider Giving to ASTCT to Support the Next Generation of Science

by Dr. Pavan Reddy, ASTCT President

ASTCT Town Hall on Race Examines Barriers for African Americans in Health Care—Both Personally and Professionally

07.07.20

ASTCT Town Hall on Race Examines Barriers for African Americans in Health Care—Both Personally and Professionally

by Kate Jacobson

Policy Perspectives: Continuing to Track COVID-19

07.01.20

Policy Perspectives: Continuing to Track COVID-19

by Alycia Maloney

Pharmacy SIG Literature Update: Novel GVHD Prophylaxis Regimens and More

06.30.20

Pharmacy SIG Literature Update: Novel GVHD Prophylaxis Regimens and More

by Katie Gatwood

COVID-19 and Blinatumomab Therapy: “First Do No Harm”

06.17.20

COVID-19 and Blinatumomab Therapy: “First Do No Harm”

by Eleanor Mayfield, ELS

Panel Addresses the Use of MRD in Clinical Decision Making

06.15.20

Panel Addresses the Use of MRD in Clinical Decision Making

by Eleanor Mayfield, ELS

NGS-MRD Assay Shows Promise in Real-World Analysis

06.12.20

NGS-MRD Assay Shows Promise in Real-World Analysis

by Eleanor Mayfield, ELS

Dr. Lisa Filipovich—A Leader in Pediatric Immune Deficiency and Stem Cell Transplant—Died Peacefully

06.11.20

Dr. Lisa Filipovich—A Leader in Pediatric Immune Deficiency and Stem Cell Transplant—Died Peacefully

by Kate Jacobson

Joint Statement from ASTCT, CIBMTR, FACT, ISCT and EBMT

06.08.20

Joint Statement from ASTCT, CIBMTR, FACT, ISCT and EBMT

by ASTCT, CIBMTR, FACT, ISCT & EBMT

Racism Has No Place Here – And We Need to Be the Change

06.03.20

Racism Has No Place Here – And We Need to Be the Change

by Dr. Pavan Reddy, ASTCT President

New Leaders at ASTCT and CIBMTR Provide Guidelines and Measures for Combating COVID-19 and Protecting Transplant Patients

06.02.20

New Leaders at ASTCT and CIBMTR Provide Guidelines and Measures for Combating COVID-19 and Protecting Transplant Patients

by ASTCT & CIBMTR

Policy Perspectives: Coronavirus Update

06.02.20

Policy Perspectives: Coronavirus Update

by Alycia Maloney

This Summer, Consider Giving to ASTCT to Support the Next Generation of Science

06.01.20

This Summer, Consider Giving to ASTCT to Support the Next Generation of Science

by Dr. Pavan Reddy, ASTCT President

An In-Depth Look at the Past and Future of Bispecific Antibodies

05.31.20

An In-Depth Look at the Past and Future of Bispecific Antibodies

by Eleanor Mayfield, ELS

Study Finds that MRD Negativity Correlates with Health-Related Quality of Life and Cost Effectiveness

05.29.20

Study Finds that MRD Negativity Correlates with Health-Related Quality of Life and Cost Effectiveness

by Eleanor Mayfield, ELS

Talking to your Patients About MRD

05.27.20

Talking to your Patients About MRD

by Kate Jacobson

Jean Sanders, MD, Reflects on Her Passion for BMT and Cellular Therapy

05.25.20

Jean Sanders, MD, Reflects on Her Passion for BMT and Cellular Therapy

by Kate Jacobson

New Data at ASCO Highlights Utility of MRD Monitoring

05.22.20

New Data at ASCO Highlights Utility of MRD Monitoring

by Kate Jacobson

Coping with COVID-19: How to Support Your Patients and Yourself Mentally and Emotionally

05.05.20

Coping with COVID-19: How to Support Your Patients and Yourself Mentally and Emotionally

by ASTCT Social Work SIG

As We Begin to Shift to the New Normal, Let’s Not Forget the Lessons of COVID-19

05.04.20

As We Begin to Shift to the New Normal, Let’s Not Forget the Lessons of COVID-19

by Dr. Pavan Reddy, ASTCT President

Pharmacy SIG Literature Update: CAR-T Cells for Mantle Cell Lymphoma and More

05.01.20

Pharmacy SIG Literature Update: CAR-T Cells for Mantle Cell Lymphoma and More

by Katie Gatwood

An ASTCT Member Recalls His Work with Bone Marrow Transplants on Patients After the Chernobyl Nuclear Disaster

04.30.20

An ASTCT Member Recalls His Work with Bone Marrow Transplants on Patients After the Chernobyl Nuclear Disaster

by ASTCT

COVID-19 & Leadership

04.21.20

COVID-19 & Leadership

by Dr. Navneet Majhail, ASTCT Past President

BiTE Therapy in Multiple Myeloma

04.13.20

BiTE Therapy in Multiple Myeloma

by Kate Jacobson

Novel Blood Biopsy Detects MRD in Early-Stage Breast Cancer

04.10.20

Novel Blood Biopsy Detects MRD in Early-Stage Breast Cancer

by Kate Jacobson

Joint Letter Urges Department of Health and Human Services to Ensure Access to Domestic and International Bone Marrow Transport

04.07.20

Joint Letter Urges Department of Health and Human Services to Ensure Access to Domestic and International Bone Marrow Transport

by

ASTCT Continues to Support You Through COVID-19

04.07.20

ASTCT Continues to Support You Through COVID-19

by Dr. Pavan Reddy, ASTCT President

Pharmacy SIG Literature Update: Haploidentical Stem Cell Transplantations for Patients with Lymphoma

04.06.20

Pharmacy SIG Literature Update: Haploidentical Stem Cell Transplantations for Patients with Lymphoma

by Brandi Ayers

COVID-19 and Stem Cell Graft Cryopreservation: What’s the Fuss About?

04.06.20

COVID-19 and Stem Cell Graft Cryopreservation: What’s the Fuss About?

by Dr. Mehdi Hamadani

ASTCT Sends Letter to Legislative Leaders on PPE

03.24.20

ASTCT Sends Letter to Legislative Leaders on PPE

by ASTCT

Updates on COVID-19 from the ASTCT President

03.23.20

Updates on COVID-19 from the ASTCT President

by Pavan Reddy, MD

Recent Study Yields Promising Results of Emerging Therapies

03.23.20

Recent Study Yields Promising Results of Emerging Therapies

by

A Message from ASTCT President Pavan Reddy on COVID-19

03.17.20

A Message from ASTCT President Pavan Reddy on COVID-19

by Dr. Pavan Reddy, ASTCT President

Coronavirus Funding Legislation

03.17.20

Coronavirus Funding Legislation

by Alycia Maloney

Dr. David S. Hong Discusses Multitargeted Therapeutics, Their Implications in Medicine

03.13.20

Dr. David S. Hong Discusses Multitargeted Therapeutics, Their Implications in Medicine

by Sydney Scarbrough

The Evolving Role of MRD in Hematologic Malignancies

03.06.20

The Evolving Role of MRD in Hematologic Malignancies

by Kate Jacobson

New Paper Explores the Application of ASTCT’s Grading System and Implications for Management of CAR T-cell Toxicity

03.02.20

New Paper Explores the Application of ASTCT’s Grading System and Implications for Management of CAR T-cell Toxicity

by Kate Jacobson

Assessing Leukemia Patients by Using MRD Testing

02.19.20

Assessing Leukemia Patients by Using MRD Testing

by Kate Jacobson

Passing the Baton and Looking for a New Future: A Final Message from Dr. Navneet Majhail

02.10.20

Passing the Baton and Looking for a New Future: A Final Message from Dr. Navneet Majhail

by Dr. Navneet Majhail, ASTCT President

Pharmacy SIG Literature Update: AlloHCT for HIV Patients and More

02.06.20

Pharmacy SIG Literature Update: AlloHCT for HIV Patients and More

by Brandi Ayers

Biotech Start-Up Adaptive Biotechnologies Looks at Innovative Diagnostic Kits, Including MRD

02.02.20

Biotech Start-Up Adaptive Biotechnologies Looks at Innovative Diagnostic Kits, Including MRD

by Kate Jacobson

MRD Status an Important Prognostic Factor in Pediatric B-Lymphoblastic Leukemia, Study Says

01.29.20

MRD Status an Important Prognostic Factor in Pediatric B-Lymphoblastic Leukemia, Study Says

by Kate Jacobson

Data on Emerging Treatments in Myeloma Unveiled at ASH

01.27.20

Data on Emerging Treatments in Myeloma Unveiled at ASH

by Kate Jacobson

FDA Finalizes 2018 Guidance on Use of Minimal Residual Disease

01.27.20

FDA Finalizes 2018 Guidance on Use of Minimal Residual Disease

by Kate Jacobson

FACT Update: Join Us at the 2020 TCT Meetings

01.20.20

FACT Update: Join Us at the 2020 TCT Meetings

by Mikaela VanMoorleghem

Sagar Lonial, MD, Discusses Role of Anti-BCMA Therapies

01.16.20

Sagar Lonial, MD, Discusses Role of Anti-BCMA Therapies

by Kate Jacobson

Adaptive and Genentech Partner to Use clonoSEQ® Assay to MRD in Study of Chronic Lymphocytic Leukemia Patients

01.16.20

Adaptive and Genentech Partner to Use clonoSEQ® Assay to MRD in Study of Chronic Lymphocytic Leukemia Patients

by Adaptive Biotechnologies

Policy Perspectives: Recapping the 2019 Calendar Year with the Government Funding Bill

01.15.20

Policy Perspectives: Recapping the 2019 Calendar Year with the Government Funding Bill

by Alycia Maloney

Dr C. Ola Landgren: MRD Is a Growing Topic of Interest in Cancer

01.10.20

Dr C. Ola Landgren: MRD Is a Growing Topic of Interest in Cancer

by Kate Jacobson

The Role of MRD in Multiple Myeloma

01.10.20

The Role of MRD in Multiple Myeloma

by ASTCT Talks

Looking Ahead to the New Year and New Opportunities

01.10.20

Looking Ahead to the New Year and New Opportunities

by Dr. Navneet Majhail, ASTCT President

Complete Response, MDR Negativity Linked to Lower Relapse Risk in Relapsed/Refractory AML

01.03.20

Complete Response, MDR Negativity Linked to Lower Relapse Risk in Relapsed/Refractory AML

by Kate Jacobson

Lifetime Achievement Award Winner Dr. Keith Sullivan Reflects on His Career and Passion

12.13.19

Lifetime Achievement Award Winner Dr. Keith Sullivan Reflects on His Career and Passion

by Kate Jacobson

Policy Perspectives: Congress' Last Ditch Efforts, Drug Pricing Updates and More

12.12.19

Policy Perspectives: Congress' Last Ditch Efforts, Drug Pricing Updates and More

by Alycia Maloney

Pharmacy SIG Literature Update: The Effect of Enteral and Parenteral Nutrition and More

12.09.19

Pharmacy SIG Literature Update: The Effect of Enteral and Parenteral Nutrition and More

by Brandi Ayers

FACT Update: Join Us in Paris for the Cord Blood Inspection and Accreditation Workshop, and More

12.06.19

FACT Update: Join Us in Paris for the Cord Blood Inspection and Accreditation Workshop, and More

by Mikaela VanMoorleghem

As 2019 Ends, Let's Reflect On Another Great Year

12.04.19

As 2019 Ends, Let's Reflect On Another Great Year

by Dr. Navneet Majhail, ASTCT President

Remembering Dr. Robert Hartzman, A Leading Force in Hematopoietic Stem Cell Transplant

11.25.19

Remembering Dr. Robert Hartzman, A Leading Force in Hematopoietic Stem Cell Transplant

by Kate Jacobson

An Institutional Membership Opens Doors for Everyone

11.18.19

An Institutional Membership Opens Doors for Everyone

by Kate Jacobson

Pharmacy SIG Literature Update: PTCy for GVHD Prophylaxis and More

11.07.19

Pharmacy SIG Literature Update: PTCy for GVHD Prophylaxis and More

by Brandi Anders

Policy Perspectives: Drug Pricing Legislation and More

11.05.19

Policy Perspectives: Drug Pricing Legislation and More

by Alycia Maloney

ASTCT Creates Powerful Possibilities -- Both Personally and Professionally

11.04.19

ASTCT Creates Powerful Possibilities -- Both Personally and Professionally

by Dr. Navneet Majhail, ASTCT President

Pharmacy SIG Literature Update: Cryotherapy as Prophylaxis Against Oral Mucositis and More

10.18.19

Pharmacy SIG Literature Update: Cryotherapy as Prophylaxis Against Oral Mucositis and More

by Brandi Anders

Doctor Reflects on Patient Care After Allogenic Transplant

10.11.19

Doctor Reflects on Patient Care After Allogenic Transplant

by Kate Jacobson

Policy Perspectives: ASTCT's HOPPS Comment Letter and More

10.04.19

Policy Perspectives: ASTCT's HOPPS Comment Letter and More

by Alycia Maloney

FACT Announces Events at 2020 TCT Meetings of ASTCT and CIBMTR

10.01.19

FACT Announces Events at 2020 TCT Meetings of ASTCT and CIBMTR

by Mikaela VanMoorleghem

You Can Make a Difference: Join the ASTCT Board!

10.01.19

You Can Make a Difference: Join the ASTCT Board!

by ASTCT

ASTCT Pharmacy SIG Summer 2019 Newsletter

09.20.19

ASTCT Pharmacy SIG Summer 2019 Newsletter

by Brandi Anders

As the Colors Change, So Do We at ASTCT

09.05.19

As the Colors Change, So Do We at ASTCT

by Dr. Navneet Majhail, ASTCT President

Policy Perspectives: IPPS Final Rule, CMS Final NCD on CAR-T and More

09.03.19

Policy Perspectives: IPPS Final Rule, CMS Final NCD on CAR-T and More

by Alycia Maloney

FACT Update: FACT-SBTMO Joint Accreditation Program Launched in Brazil and More

09.02.19

FACT Update: FACT-SBTMO Joint Accreditation Program Launched in Brazil and More

by Mikaela VanMoorleghem

Pharmacy SIG Literature Update: Autologous HCT in Myeloma Patients Over 75 and More

09.01.19

Pharmacy SIG Literature Update: Autologous HCT in Myeloma Patients Over 75 and More

by Brandi Anders

Pharmacy SIG Literature Update: Autologous HCT in Myeloma Patients Over 75 and More

08.27.19

Pharmacy SIG Literature Update: Autologous HCT in Myeloma Patients Over 75 and More

by Brandi Anders

Pharmacy SIG Literature Update: Mortality Analysis of Letermovir Prophylaxis for CMV and More

08.16.19

Pharmacy SIG Literature Update: Mortality Analysis of Letermovir Prophylaxis for CMV and More

by Brandi Anders

Saying Goodbye to a BMT Pioneer, Dr. John Hansen

08.14.19

Saying Goodbye to a BMT Pioneer, Dr. John Hansen

by Kate Jacobson

FACT Update: Complete FACT's Education Survey, Read their Latest Paper and More

08.12.19

FACT Update: Complete FACT's Education Survey, Read their Latest Paper and More

by Mikaela VanMoorleghem

ASTCT Submits Letter to CMS on National Coverage Decision for CAR T-cell Therapy for Cancers

08.08.19

ASTCT Submits Letter to CMS on National Coverage Decision for CAR T-cell Therapy for Cancers

by ASTCT

Policy Perspectives: ASTCT and ASH Have Joint Call with CMS, Update on #RaisetheCaps and More

08.07.19

Policy Perspectives: ASTCT and ASH Have Joint Call with CMS, Update on #RaisetheCaps and More

by Alycia Maloney

Remembering Dr. Wesley Miller, a Pioneer at the University of Minnesota

08.06.19

Remembering Dr. Wesley Miller, a Pioneer at the University of Minnesota

by Kate Jacobson

As Summer Begins to Sunset, Students and Standards Continue to Inspire

08.02.19

As Summer Begins to Sunset, Students and Standards Continue to Inspire

by Dr. Navneet Majhail, ASTCT President

Amazing Education and Fellowship: A Perspective from CRTC

07.29.19

Amazing Education and Fellowship: A Perspective from CRTC

by By Akshay Sharma, MBBS -- St. Jude Children's Research Hospital

Reflecting On a Life-Altering Diagnosis: One BMT Professional’s Journey

07.19.19

Reflecting On a Life-Altering Diagnosis: One BMT Professional’s Journey

by Darren Johnson, PA-C - The Children's Hospital at TriStar Centennial, Sarah Cannon Research Institute

When it Comes to Work-Life Balance, Leaning on Others and Problem Solving is Key

07.09.19

When it Comes to Work-Life Balance, Leaning on Others and Problem Solving is Key

by Dr. Navneet Majhail, ASTCT President

Join ASTCT at the RITN Workshop in July

07.02.19

Join ASTCT at the RITN Workshop in July

by ASTCT

Thank You Dr. Miguel Perales

07.02.19

Thank You Dr. Miguel Perales

by ASTCT

Teamwork Makes the Dream Work: Coming Together Makes Us Stronger

06.04.19

Teamwork Makes the Dream Work: Coming Together Makes Us Stronger

by Dr. Navneet Majhail, ASTCT President

An International Affair: One Doctor Shares His Story of Helping Cellular Therapy Doctors Around the World

05.30.19

An International Affair: One Doctor Shares His Story of Helping Cellular Therapy Doctors Around the World

by Kate Jacobson

Theme picker

Search